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The Hedgehog (Hh) receptor Patched1 is a well-established tumour suppressor. 
Its C-terminal domain (CTD) interacts with autophagy-related protein 101 
(ATG101) to inhibit autophagic flux. The first part of my research focused on 
understanding this interaction. In Chapter 3, I show that endogenous Patched1 
is sufficient to restrain autophagic flux. On Chapter 4, I investigated the functional 
consequences of three somatic mutations found in the CTD in human cancer 
databases. Results show that two of these lose the interaction with ATG101 
causing an apparent increase in autophagic flux. These results strengthen a 
tumour suppressor role of Patched1 in addition to, and independently of, its 
function as Smoothened repressor.  
 
In  Chapter 5, I validated and characterised the physical interaction between 
Integral membrane protein 2A (ITM2A) and Patched1. While the findings indicate 
that ITM2A, like Patched1, inhibits autophagic flux, the results suggest that they 
work independently. 
Unexpectedly, ITM2A had a negative effect on the stability of Patched1, which 
suggested  a crosstalk with the Hh canonical pathway. Further analysis revealed 
that ITM2A negatively regulates Gli1 and Gli2 transcriptional activity. In Chapter 
6, I showed a potential inhibitory function of Itm2a on autophagic flux during 
myogenic differentiation. Partial silencing of Itm2a delayed both myogenic 
differentiation and upregulation of cyclin D3 necessary for cell cycle exit of 
myoblasts. Proteomic analysis was used to find potential ITM2A-interacting 
proteins, which suggest a potential role in regulation of CDK1 and CDK2NA and 
of selective autophagy, which will be explored in future studies.  
v 
 
In summary, this doctoral research uncovered a novel role of ITM2A as a negative 
regulator of the canonical Hh pathway and as a Patched1-binding  partner.  
Results suggest that ITM2A might be a specific regulator of selective autophagy 
during skeletal muscle differentiation as opposed to a more general role of 
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Chapter 1                                                                       
Literature Review 
 
1.1 Hedgehog Signalling Pathway   
The correct functioning of multicellular organisms relies on highly orchestrated 
signalling pathways and their regulation is important for the cellular response to 
the ever-changing cellular environment. Dysregulation of these signalling 
cascades is linked to different human pathologies (Lodish et al., 2000; 
Valdespino-Gómez, et al., 2015). The Hedgehog (Hh) signalling pathway is a 
major regulator of embryonic development in vertebrates and invertebrates 
(McMahon et al., 2003). The Hh gene was first identified in a study designed to 
find embryonic mutants in Drosophila melanogaster. The Hh gene was shown to 
be involved in the patterning and in the polarity of the segments during Drosophila 
development (Wieschaus and Nüsslein-Volhard, 1980). Later, vertebrate 
homologues of the Hh gene were identified, including the mammalian members 
of the Hh family Sonic, Indian and Desert Hh (Echelard et al.,1993; Ingham and 
McMahon, 2001). The role of Hh signalling in embryonic development involves 
cell specification, cell proliferation, cell differentiation and cell survival. The Hh 
signalling pathway is involved in the formation of most of mammals’ organs. The 
effect of Hh signalling is dependent on the cell type, on the concentration (since 
it acts as a morphogen) and on the time the cells are subjected to Hh stimulus 
(Ingham and McMahon, 2001).  Hh signalling is also involved in the maintenance 
of homeostasis and regeneration of different adult structures, and aberrant 
signalling has been linked to tumorigenesis and different types of cancer in 
mammals (Petrova and Joyner, 2014; Bangs and Anderson, 2017). 






1.1.1 Core components of the Hh signalling pathway 
Functional Hh proteins are produced by the autocatalytic cleavage of the Hh 
precursor (45 kDa). This cleavage results in the generation of two fragments. The 
N-terminal fragment (Hh-N) has a molecular weight of around 20 kDa while the 
C-terminal fragment (Hh-C) has a molecular weight of around 25 kDa. The amino 
terminal fragment is involved in the signalling activity of the protein, while the C-
terminal fragment plays a role in the autocatalytic cleavage of the precursor form 
of the Hh protein and aids in the cholesterol modification carried out during the 
processing of the Hh-N fragment. During processing, the N-terminal fragment is 
modified by covalent addition of a cholesterol  moiety  to the carboxyl group of its 
C-terminus. Additionally, after cholesterol binding, maturation of Hh-N also 
includes the attachment of a palmitate group into its N-terminal cysteine. The 
efficient processing of the Hh proteins is necessary for their functionality (Lee et 
al., 1994; Bumcrot et al., 1995; Porter et al., 1995; Porter et al., 1996; Pepinsky 
et al.,1998). Once the Hh-N fragment has been processed and secreted, it 
remains anchored in the plasma membrane. The release of the lipid-modified and 
functional Hh protein from the producing cell is carried out by the 12-pass 
transmembrane protein Dispatched (Disp) that functions as a sterol transporter 
protein. Hh proteins are secreted to the extracellular matrix and can exert their 
activity locally and also be diffused over long distances to reach the target cells 
(Burke et al., 1999; Ma et al., 2002; Yang et al., 2015).  
Similar to most of the components of the Hh signalling pathway, Patched (Ptc) 
was first described in Drosophila and characterised as a gene that encodes for a 
large multi-pass transmembrane protein expressed during embryogenesis and 
involved in the regulation of cell patterning (Nakano et al., 1989; Hidalgo and 






Ingham, 1990; Ingham, 1991). Later, its role as the receptor and repressor of the 
Hh signalling pathway was established (Ingham et al., 1991; Chen and Struhl, 
1996; Stone et al.,1996).  
There are two mammalian homologues of Drosophila Ptc: Patched1 (PTCH1) 
and Patched2 (PTCH2). PTCH1 is the most abundant and the most broadly 
studied mammalian receptor of the Hh pathway. PTCH1 is a tumour suppressor 
gene that encodes for a 12-pass transmembrane protein. PTCH1 is negatively 
regulated by the Hh proteins and, in the absence of Hh ligands it actively 
represses the activity of Smoothened (Smo). PTCH1 localises in the plasma 
membrane, its C-terminal domain (CTD) and N-terminus are intracellular while its 
two large loops are located extracellularly and physically interact and bind to the 
Hh proteins to activate the pathway. PTCH1 has similarity with the resistance 
nodulation division (RND) family of bacterial transporters, commonly used to 
pump lipophilic substrates through membranes. PTCH1 also contains a putative 
sterol sensing domain (SSD) of about 180 amino acids long that is involved in 
cholesterol trafficking (Capdevila et al., 1994; Stone et al.,1996; Loftus et al., 
1997; Johnson et al., 2002; Taipale et al., 2002; Rohatgi et al., 2007; Robbins et 
al., 2012).  
The CTD of PTCH1 is involved in the regulation of important functions. Studies 
show that the soluble CTD is enough to exhibit the pro-apoptotic phenotype 
observed when full length PTCH1 is expressed. The CTD regulates the 
intracellular localization of PTCH1 and also its turnover (Thibert et al., 2003; Lu 
et al., 2006; Kawamura et al., 2008).  
Mutations that render PTCH1 inactive and that lead to the unregulated activation 
of the Hh signalling pathway are linked to abnormalities in the developmental 






stage and to different types of cancer. In particular, mutations in human PTCH1 
are linked to the development of basal cell nevus syndrome (BCNS), also referred 
to as Gorlin’s syndrome, characterised by minor skeletal defects and high 
incidence of medulloblastoma and basal cell carcinoma (BCC). Somatic 
mutations of PTCH1 are causal of almost 90% sporadic BCC, the most common 
skin cancer (Hahn et al., 1996; Johnson et al., 1996; Epstein, 2008). 
PTCH2 is another receptor of the Hh signalling pathway. It shares ~50% of 
homology with PTCH1. The CTD is the least conserved part between these two 
proteins. PTCH2 gene encodes for a slightly smaller protein, compared to 
PTCH1, that exhibits lower activity for inhibition of SMO in the absence of Hh 
protein. The expression pattern and signalling varies between PTCH1 and 
PTCH2. Nonetheless, the transcription of PTCH2, as well as the expression of 
PTCH1, depends on the activation of Gli transcription factors and serves as a 
negative feedback (Kawamura et al., 2008; Robbins et al., 2012). 
The Hh signalling pathway also requires the expression of co-receptors that bind 
to the Hh ligands. These co-receptors are conserved between Drosophila and 
mammals. The first Hh co-receptor to be identified was Interference Hedgehog 
(Ihog). It was described as a positive regulator of the Hh pathway in Drosophila. 
A second co-receptor, Brother of Ihog (Boi), was also identified in Drosophila. Boi 
is a homologue of the Ihog protein that carries out the same function as Ihog. 
Ihog is a type I (single pass) transmembrane protein. Ihog’s intracellular domain 
is not conserved while its larger extracellular region is composed of four 
immunoglobin-like (Ig) domains and two fibronectin type III (FNIII) domains. The 
interaction of Ihog with Hh ligands is mediated by the first FNIII domain (FN1) 






while the interaction of this co-receptor with Ptc is through its second FNIII 
domain (FN2) (Lum et al., 2003; Yao et al., 2006; Zheng et al., 2010). 
There are two mammalian homologues of Ihog: Cell adhesion molecule 
Downregulated by Oncogenes (CDO) and Brother of CDO (BOC). These interact 
with the Hh ligand through their FNIII domain in a fashion comparable to the one 
described for Ihog. CDO and BOC are type I transmembrane proteins, their 
extracellular region contains four or five Ig domains, respectively, and two or three 
FNIII domains, respectively. Expression of these co-receptors is involved in the 
activation of the Hh signalling pathway, their activity is redundant to each other 
and silencing of both co-receptors does not completely abolish activation of the 
Hh signalling (Okada et al., 2006; Tenzen et al., 2006; Yao et al., 2006). Growth 
arrest-specific 1 (GAS1) is a third co-receptor of the vertebrate Hh pathway. 
Different from CDO and BOC, GAS1 is a cell surface protein that does not contain 
a transmembrane domain, instead localises to the cellular membrane by a 
glycosylphosphatidylinositol (GPI) anchor. As CDO and BOC, GAS1 is a positive 
regulator of Hh signalling. Abrogation of GAS1 expression is characterised by a 
reduced Hh signalling, however it does not inhibit it completely (Allen et al., 2007; 
Martinelli and Fan, 2007; Beachy et al., 2010). The importance of these three co-
receptors in the mammalian Hh signalling pathway was appreciated in a study 
that showed that a Shh mutant, that retains the interaction with PTCH1 but that 
is unable to bind to any of the co-receptors (CDO, BOC and GAS1) cannot 
activate the pathway (Izzi et al., 2011). 
The Smoothened (Smo) gene was first identified in Drosophila as a polarity gene 
required for embryonic cell patterning. Smo encodes for a 7-transmembrane 
protein that is structurally similar to G-protein coupled receptors (GPCRs). Its role 






in the Hh signalling was first thought to be the receptor of the pathway, later it 
was shown that Smo mediates the activation of Hh signalling by triggering the 
activation of downstream components. The activity of Smo is regulated 
downstream Hh and Ptc. In Drosophila, the C-tail of Smo is rich in Ser/Thr 
phosphorylation sites and this fragment mediates its role in the Hh pathway. The 
binding of the Hh protein to Ptc induces the phosphorylation of the C-tail of Smo, 
which in turn produces a change in the conformation state of Smo, promoting its 
multimerisation. Smo is then translocated to the plasma membrane (Alcedo et 
al., 1996; van den Heuvel and Ingham, 1996; Hammerschmidt et al., 1997; Chen 
et al., 2002). 
SMO is the only mammalian homologue of Drosophila Smo. The most conserved 
regions of the protein, between Drosophila and mammals, are the 
transmembrane domains, while the most variable region is the C-tail. Mammalian 
SMO is also phosphorylated upon Hh ligand stimulation and transported into the 
primary cilium where it accumulates. However, the components involved in its 
phosphorylation differ from the ones involved in Drosophila. Nonetheless, SMO 
phosphorylation also induces a conformational change required for its activation 
(Huangfu and Anderson, 2006; Briscoe and Thérond, 2013). 
 
1.1.2 Overview of the regulation of the Hh signalling pathway in 
Drosophila  
In Drosophila, the Hh signalling pathway is activated when the Hh protein binds 
to Ptc. In the absence of ligand, Ptc constitutively represses the activity of the 
Smo (Alcedo, et al., 1996). When Smo is repressed by Ptc, the kinesin-like 
protein Costal 2 (Cos2) forms a complex with Cubitus interruptus (Ci), Fused (Fu) 






and Suppressor of fused (Su(fu)). In this complex Ci is phosphorylated by protein 
kinase A (PKA), casein kinase 1 (CK1) and glycogen synthase kinase 3β 
(GSK3β), it is also retained in the cytoplasm and processed into its repressor 
form (CiR). In the presence of the Hh ligand, Ptc releases Smo inhibition, Smo is 
then stabilised and phosphorylated by CK1, casein kinase 2 (CK2), G protein-
coupled receptor kinase 2 (Gpcrk2) and PKA. Active Smo interacts with Cos2 
and Ci is released from the complex. Active full-length Ci is then translocated to 
the nucleus where it regulates the signalling pathway by activating the 
transcription of the Hh target genes (Robbins et al., 1997; Chen et al., 1999; 
Wang et al., 2000; Lum et al., 2003; Zhao et al., 2007; Yang et al., 2015). 
 
1.1.3 Canonical Hh signalling pathway in vertebrates  
The core components and the general mechanisms of the Hh signalling pathway 
are highly conserved. However, there is variability in the specific design of the 
pathway between different species. The vertebrate Hh signalling pathway 
requires extra components that are not found in Drosophila. In vertebrates, Hh 
signalling greatly depends on the presence of an additional organelle: the primary 
cilium. The primary cilium is a highly specialised microtubule-based organelle that 
forms from the basal body as immotile flagella on the surface of most cells that 
are not undergoing cell division (Simpson et al., 2009; Yang et al., 2015; Bangs 
and Anderson, 2017).  
Although the presence of primary cilia has not been widely described in immune 
cells, it has been shown that a region known as the immune synapse, could 
potentially function as the equivalent of the primary cilium in these cells. The 
immune synapse is the region used by immune cells to interact with target cells 






(Stinchcombe and Griffiths, 2014; Prosser and Morrison, 2015). Furthermore, the 
presence of primary cilia in lymphocytes was described in-vitro. Jurkat T-
lymphocytes and NALM-6 B cells were serum starved to induce the formation of 
functional primary cilia (Prosser and Morrison, 2015).  
The primary cilium has an important role in the coordination of extracellular and 
intracellular signals of a number of signalling cascades involved in development, 
among them the Hh pathway (Simpson et al., 2009; Yang et al., 2015; Bangs and 
Anderson, 2017). 
In contrast to Hh signalling in Drosophila that is regulated by a single Hh ligand, 
mammalian Hh signalling is activated by three ligands: Sonic Hedgehog (Shh), 
Indian Hedgehog (Ihh) and Desert Hedgehog (Dhh) (Echelard et al.,1993; Riddle 
et al., 1993; Ingham and McMahon, 2001). These Hh proteins are expressed in 
different tissues and, among them, Shh is the most widely expressed. Shh has 
important functions in the nervous system including specification of different cell 
types, control of the cell fate and the patterning of the limbs and digits (Zhu et al., 
2008).  Ihh is expressed and required for the development of bone and cartilages 
and plays important roles in cytotoxic T cell function (de la Roche et al., 2013). In 
some tissues, Shh and Ihh have similar functions. Dhh is expressed in male 
gonads, where it is required for development of germ cells and in Schwann cells 
where it controls the development peripheral nerves sheaths. These three Hh 
ligands bind to PTCH1, albeit with a different potency and therefore there is 
variability in the response observed with each protein (Bitgood et al., 1996; Young 
et al., 1996; Pathi et al., 2001; Cai et al., 2008). 
In the absence of Hh ligand, PTCH1 is located in the primary cilium repressing 
SMO activity and inhibiting SMO transport into the cilium. When the Hh proteins 






are present, PTCH1 is inhibited, excluded out of the primary cilium, internalised 
and degraded (along with the Hh ligand). Binding to the Hh ligand alleviates 
PTCH1 suppression of SMO which renders SMO free to move into the primary 
cilium. Accumulation of SMO within the cilia triggers the events required for the 
regulation of the Glioma-associated oncogene (Gli) family of zinc finger 
transcription factors, the vertebrate homologue of Ci. The Gli family of proteins 
are the downstream effectors of the Hh signalling pathway in vertebrates (Figure 
1.1) (Kinzler et al., 1988; Rohatgi et al., 2007; Nozawa et al., 2013).  
There are three Gli proteins: Gli1, Gli2 and Gli3; and each fulfils a specific function 
to regulate the Hh pathway. While Gli2 and Gli3 have dual roles in the regulation 
of the pathway, full length Gli1 is expressed as a response of the activation of the 
signalling cascade and has an exclusive transcriptional activator role. The main 
role of Gli1 and Gli2 is as transcriptional activators. Gli2 and Gli3 can act as 
activators or repressors depending of the state (on or off) of the Hh signalling 
pathway. When there is no ligand bound to the receptor PTCH1, Gli2 and Gli3 
are processed into their repressor forms: Gli2R and Gli3R respectively. Even 
though Gli2 and Gli3 have this dual role, Gli3 is considered the main repressor of 
the pathway and the primary role of Gli2 is transcriptional activator (Dai et al., 
1999; Sasaki et al., 1999). 
Kinesin member 7 (Kif7) and SUFU the mammalian homologues of Drosophila 
Cos2 and Su(fu) respectively, are located in the primary cilium. Kif7 has two main 
roles in the Hh pathway: in the absence of Hh proteins, Kif7 and PKA at the base 
of the primary cilium, are involved in the phosphorylation cascade that is required 
for the proteolytic processing of the repressor forms Gli3R and Gli2R. However, 
the proteolytic processing of Gli2 is not as efficient as the process of Gli3 and 






while the majority of Gli3 is processed into its truncated amino-terminal repressor 
form, just some of the Gli2 is processed and is mainly degraded by the 
proteasome. Gli3R and Gli2R (less abundantly) move out of the primary cilia into 
the nucleus, repressing the transcription of Hh target genes (Pan et al., 2006; 
Pan et al., 2009; Tuson et al., 2011). 
Mammalian SUFU is an important negative regulator of the pathway, that in the 
absence of Hh protein, forms a complex with Gli2 and Gli3 to block their activation 
at the tip of the cilia. SUFU also participates in nuclear-cytosol shuttling of the Gli 
transcription factors (Humke et al., 2010; Nozawa et al., 2013). 
In the presence of the Hh protein, SMO enters the primary cilium and is 
phosphorylated, which causes the inhibition of the processing of the repressor 
forms Gli3R and Gli2R. Phosphorylation of SMO stimulates heterotrimeric Gi 
proteins, reducing PKA activity, this causes the movement of Kif7 and the 
complex formed by SUFU and full length Gli2 or Gli3 to the tip of the cilia, where 
the complex accumulates. Kif7 is involved in the dissociation of Gli2 and Gli3 from 
the complex. Once free from SUFU, these Gli proteins undergo post-translational 
modifications, not yet fully elucidated, to generate the activator forms: Gli2A and 
Gli3A, that moved out of the cilia to the cytoplasm and into the nucleus where 
they activate the transcription of the Hh target genes such as PTCH1 and Gli1 
(Pan et al., 2006; Pan et al., 2009; Tuson et al., 2011; Nozawa et al., 2013; Yang 













Figure 1.1 Simplified schematic representation of canonical Hh signalling 
in vertebrates 
In the absence of Hh ligand, PTCH1 is located in the primary cilium repressing 
both, the activity of SMO and its localisation to the cilium. Gli2 and Gli3 are held 
in the cilium by a complex formed by SUFU and Kif7. Gli2 and Gli3 are 
phosphorylated and proteolytically processed into their repressor forms which 
move to the nucleus, where they repress the transcription of Hh target genes. 
In the presence of Hh ligand, PTCH1 (along with the Hh ligand) is internalised 
and degraded. Free of PTCH1 repression, SMO  translocates to the primary 
cilium where its activation regulates the dissociation of Gli2 and Gli3 from SUFU. 
Activator forms Gli2A and Gli3A move to the nucleus, where they activate the 










Is important to highlight that PTCH1 is a target gene of the Hh signalling. 
Therefore, the activation of the pathway generates a negative feedback loop. The 
machinery and mechanisms required to activate the Gli-mediated expression of 
Hh target genes through this route of signalling and trafficking of components is 
known as the Hh canonical pathway. However, when the activity of Hh signalling 
does not depend on the activation of the Gli family, the signalling cascade is 
referred as the non-canonical Hh pathway (Ingham et al.,1991; Ruiz i Altaba, 
1999; Sasaki et al., 1999; Jenkins D. 2009; Brennan et al., 2012). 
 
1.1.4 Non-canonical Hh signalling pathway  
The non-canonical signalling pathway diverges from the canonical paradigm as 
it does not result in the Gli-dependent activation of the transcription of Hh target 
genes. Non-canonical signalling pathway is involved in the regulation of essential 
processes required for mammalian development and for maintenance of adult 
structures. Two different subcategories of the non-canonical Gli-independent Hh 
pathway have been described. Type I is SMO-independent while type II occurs 
downstream of SMO. Examples of the responses observed in a non-canonical 
type I Hh signalling include cell survival and cellular proliferation. While non-
canonical type II participates in the regulation of Ca2+ flux, cell migration and 
rearrangement of the actin cytoskeleton (Figure 1.2) (Jenkins D. 2009; Chinchilla 
et al., 2010; Brennan et al., 2012; Riobo, 2012; Robbins et al., 2012; Carballo et 











Figure 1.2 Simplified schematic representation of type I and type II non-canonical Hh signalling in vertebrates 
Non-canonical type I Hh signalling is independent of SMO and regulated by Hh ligands. Non-canonical type II is dependent of SMO activity 
and, in most cases, mediated by Gi proteins. Examples of specific responses of the different types of non-canonical signalling are 
summarised in the graphic. Created with BioRender.com.  






Type I non-canonical signalling is dependent on the activity of PTCH1 alone. 
Apoptosis, a form of programmed and controlled cell death, is in part, regulated 
by non-canonical type I Hh signalling. When PTCH1 is expressed in mammalian 
cells (HEK293T and neuroblasts), and in the absence of Hh ligand, apoptosis is 
enhanced following a mechanism that is not inhibited by activation of SMO. The 
pro-apoptotic activity of PTCH1 requires the cleavage by caspase 9, of a region 
within the CTD of PTCH1 (D1392). Hence, the pro-apoptotic activity of PTCH1 is 
mediated by the CTD (Kerr et al., 1972; Thibert et al., 2003; Chinchilla et al., 
2010; Brennan et al., 2012). Type I non-canonical Hh signalling is also involved 
in regulation of cell division. PTCH1 interacts with phosphorylated cyclin B1. This 
interaction affects the normal cellular localization of cyclin B1 causing its 
movement to the cytoplasm and out of the nucleus and inhibiting the completion 
of mitosis. Expression of Shh was shown to prevent the interaction of PTCH1 with 
phosphorylated cyclin B1. In the presence of Shh, cyclin B1 was found in the 
nucleus where it promotes cellular proliferation (Barnes et al., 2001; Brennan et 
al., 2012). 
Non-canonical Hh signalling type II is dependent of SMO activity, in the majority 
of cases shown to be dependent of its function as GPCR and mediated by Gi 
proteins. The activation of small GTPases by type II non-canonical signalling is 
required for the regulation of the actin cytoskeleton. The activation of SMO in the 
presence of the Hh ligands, promotes the activation of the small GTPase RhoA 
which is necessary for the formation of actin stress fibres and for tubologenesis 
in endothelial cells. The effect of this mechanisms is fast and is not accompanied 
by the activation of the Gli family of transcription factors nor the expression of Hh 
target genes. Also, the activation of RhoA and Rac1 GTPases via non-canonical 






type II Hh signaling promotes cell migration of fibroblasts in the presence of Shh. 
This mechanism depends on the activation of SMO but the expression of Gli3R, 
that inhibits canonical pathways, does not block cell migration (Chinchilla et al., 
2010; Polizio et al., 2011; Robbins et al., 2012). In cardiac myocytes, activation 
of SMO leads to reduction of repolarising K+ currents and prolongation of the 
action potential duration, resulting in development of arrhythmias. This process 
in mediated by Gi proteins and inhibition of PKA activity (Cheng et al., 2018).  
Of relevance, recent studies show that the activation of the Gli family of 
transcription factors can also occur independently of SMO following a non-
canonical signalling. This non-canonical activation has been linked to cross-talk 
with different signalling pathways, among them RAS, transforming growth factor 
β (TGF-β) and the PI3K-AKT-mTOR Signalling. These non-canonical process 
can lead to the activation of Gli transcription factors and also to post-translational 
modification of the Gli proteins. Non-canonical activation of the Gli family is 
involved in the development of different cancer types, and as such its study is key 
for the development of new therapeutic strategies to treat cancer (Lauth and 
Toftgård, 2007; Pietrobono et al., 2019). 
The mechanisms that regulate the decision to activate canonical or non-canonical 
Hh signalling pathway have not been elucidated. However, the absence of 
primary cilium does not prevent most forms of non-canonical Hh signalling, as 
opposed to causing a complete inhibition of canonical Gli-dependent signalling. 
Nevertheless, the variety of signalling mechanisms of the Hh pathway clearly 
show that this signalling cascade should not be viewed as linear. On the contrary, 
it should be studied as a network that modulates independent and sometimes 






overlapping events through different signalling routes (Robbins et al., 2012; 
Carballo et al., 2018). 
 
1.2 Autophagy  
1.2.1 Overview of autophagy  
The word autophagy derives from the Greek words “auto” and “phagy” which 
means self-eating (De Duve and Wattiaux, 1966; Klionsky, 2008). This term is 
used to describe the evolutionary conserved mechanism by which cytoplasmic 
substrates are engulfed by a membrane and delivered to the lysosomes (in 
mammals) or vacuole (in yeast) for degradation (De Duve and Wattiaux, 1966; 
Marzella et al., 1981). In eukaryotic cells, autophagy regulates the degradation 
and recycling of different cytoplasmic components, which include, among others, 
defective organelles, protein aggregates and misfolded proteins (Cuervo and 
Dice, 1998; Kim and Klionsky, 2000). The breakdown products obtained after 
autophagic degradation are used to fulfil the metabolic requirements of the cell 
and to synthesize new components (Rabinowitz and White, 2010). Autophagy is 
important for the maintenance of cellular homeostasis. In normal conditions, 
basal autophagy functions as a quality control mechanism that regulates the 
degradation of components that can be detrimental for cell survival. It also plays 
a role in the cell’s response to stress conditions such as amino acid starvation, 
hypoxia, and pathogenic infections. Thus, upregulation of autophagy helps the 
cell to adapt to changes in the environment (Munafó and Colombo, 2001; Wang 
and Klionsky, 2003; Rabinowitz and White, 2010; Denton et al., 2015; Yoshii and 
Mizushima, 2017). 
 






1.2.2 Types of autophagy  
Depending on the particular way of enclosing and delivering the sequestered 
cargo, autophagy is classified as follows: microautophagy, chaperone-mediated 
autophagy (CMA) and macroautophagy (Figure 1.3). Microautophagy and 
macroautophagy occur in mammals and yeast, while CMA has only been 
identified in mammals (Mortimore et al., 1983; Cuervo and Dice, 1998; Mizushima 
et al., 2002; Mizushima and Komatsu, 2011; Wen and Kliionsky, 2016). 
Microautophagy, mainly studied in yeast, occurs when the lysosome or vacuole 
itself engulfs cytosolic components by invagination or protrusion of its membrane 
(Ahlberg and Glaumann, 1985; Li et al., 2012). In CMA the proteins to be 
degraded are transported directly to the lysosomes. These proteins contain a 
KFERQ-like pentapeptide motif which is recognised by chaperones and co-
chaperones (chaperone complex) found in the cytosol, among which, the most 
abundant is the heat shock cognate of 70 kDa (HSC70). Chaperones target the 
proteins to the lysosome membrane where they interact with the Lysosome-
associated membrane protein type 2A (LAMP2A) receptor and the lysosomal 
HSC70 (Lys-HSC70) for the translocation of the unfolded protein into the 
lysosomes (Chiang and Dice, 1988; Massey et al., 2004; Massey et al., 2006; 
Orenstein and Cuervo, 2010, Yoshii and Mizushima, 2017). Macroautophagy 
(henceforth referred as autophagy), the most widely studied type of autophagy, 
is highly conserved among higher eukaryotes and, in normal conditions, occurs 
constitutively at low basal levels (Mizushima, 2005). The morphological 
characteristic of autophagy is the formation of the autophagosomal vesicle 
(Arstila and Trump, 1968; Axe et al., 2008). 






Autophagy can be further categorised depending on the type of engulfed material 
for degradation. Under this classification, autophagy is divided in two types, 
selective and non-selective or bulk autophagy. These two types of autophagy can 
take place simultaneously. In non-selective autophagy the cargo is not 
specifically selected. The cytoplasmic components are commonly degraded as a 
response of nutrient or energy deprivation, therefore, its activation is important in 
a context of cell adaptation and survival to changes in nutrient availability. On the 
other hand, selective autophagy refers to the degradation of specific sequestered 
cargo such as specific organelles, and commonly occurs to maintain homeostasis 
in nutrient-rich conditions. Whole organelles can be degraded by selective 
autophagy, for example mitochondria (mitophagy), peroxisomes (pexophagy), 
protein aggregates (aggrephagy), lipid droplets (lipophagy) and pathogens 
(xenophagy). Depending of which organelle is selectively degraded, specific 
adaptor factors play a role apart from the autophagy core machinery (Yorimitsu 
and Klionsky, 2005; Wen and Kliionsky, 2016; Yoshii and Mizushima, 2017).  
Microautophagy and macroautophagy can occur in both, selective and non-
selective manner. CMA is activated purely by the selective mechanism (Klionsky 
et al., 2008). 
 







Figure 1.3 Overview of the different types of autophagy 
Autophagy can be classified in 3 different types: microautophagy, chaperone-
mediated autophagy (CMA) and macroautophagy. A. In microautophagy the 
lysosome engulfs directly the cytosolic components to be degraded. B. During 
CMA, proteins containing a KFERQ motif are targeted by chaperones, such as 
HSC70, and transported to the lysosome for internalisation and degradation. C. 
Macroautophagy is characterised by the formation of the autophagosome, a 
double-membrane transient organelle, that engulfs the cytoplasmic contents to 
be degraded and transport them to the lysosome; the autophagosome fuse with 
the lysosome to form the autolysosome, where the degradation of the engulfed 
contents takes place. Adapted from “Three Main Types of Autophagy”, by 














Autophagosomes are double-membrane vacuoles that isolate the organelle or 
the portion of the cytoplasm that contains the materials to be degraded, however 
they do not contain degradative enzymes. Therefore, they transport the 
sequestered contents to the lysosomes for degradation and recycling (Figure 
1.4) (Arstila and Trump, 1968; Axe et al., 2008). The biogenesis of the 
autophagosome involves different process of membrane remodelling carried out 
at multiple stages: induction, nucleation of the phagophore, expansion of the 
phagophore and completion of the autophagosome (maturation) (Wen and 
Kliionsky, 2016; Zhang et al., 2016). Upon autophagy induction, the signalling 
and recruitment of the autophagy initiation complexes takes place at the 
membrane sites where nucleation occurs. During nucleation, the formation of a 
specialized isolation membrane known as the phagophore is carried out. 
Expansion, occurs while the phagophore elongates by the addition of lipids that 
come from different membrane sources. The phagophore surrounds the 
cytoplasmic components in a cup-shaped structure until its edges fuse together 
to form the autophagosome. No lysosomal proteins are found in this structure 
(Klionsky, 2005; Axe et al., 2008; Hamasaki et al., 2013; Lamb et al., 2013; Yoshii 
and Mizushima, 2017). Because the phagophore surrounds the cytoplasmic 
content, there is a big range in the capacity that the autophagosome can hold. 
The size of an autophagosome varies depending on the organism and on the 
engulfed material, in mammals their diameter ranges from 0.5 to 1.5 μm 
(Mizushima et al., 2002; Wen and Kliionsky, 2016). The formation of the 
autophagosome occurs in an average of 10 minutes. Once the autophagosome 
has been conjugated with protein microtubule-associated protein 1 light chain 3 






(LC3), this transient organelle has a half-life of around 10 to 20 minutes before 
fusing with the lysosomes (Pfeifer et al., 1978; Schworer et al., 1981; Köchl et al., 
2006; Xie et al., 2008; Mijaljica et al., 2012; Melia et al., 2020). Several 
autophagosomes are formed simultaneously and, depending on the cue for the 
initiation of autophagy and on the origin of the cytoplasmic cargo, the site of the 
autophagosome formation can vary, however the basic machinery for the 
formation of new autophagosomes is conserved (Jahreiss et al., 2008; Yu et al., 
2018). The expansion of the phagophore has been linked to multiple membrane 
origins (Blommaart et al., 1997; Axe et al., 2008). The most accepted hypothesis 
about the formation of the autophagosome in mammalian cells suggests that the 
phagophore is synthesised from existing membranes such as the Endoplasmic 
reticulum (ER), Golgi and mitochondria, with the ER being the most likely origin 
(Dunn, 1990a; Dunn, 1990b; Yamamoto et al., 1990; Jahreiss et al., 2008; Lamb 
et al., 2013; Melia et al., 2020).  
The fusion of the autophagosome with the lysosome is tightly regulated, if there 
is premature fusion between the phagophore and the lysosome, the surrounded 
substrates will not be delivered (Wen and Kliionsky, 2016). When the outer 
membrane of the autophagosome fuses with the single membrane lysosome, the 
autolysosome is formed. At the final step of autophagy, the low pH inside the 
autolysosome activates the lysosomal hydrolases, these enzymes will degrade 
the engulfed contents along with the inner membrane of the autophagosome. 
Once proteins, lipids and carbohydrates have been broken down, they are 
delivered back to the cytoplasm (Deretic, 2008; Suzuki and Ohsumi, 2010; 
Devereaux et al., 2013; Peppard et al., 2014; Mauvezin et al., 2015). 
 







Figure 1.4 Schematic representation of autophagy  
The signature structure of autophagy is the autophagosome. During nucleation, 
complexes are recruited to form the phagophore, which expands to surround the 
cytoplasmic contents to be degraded. Finally a mature autophagosome is formed 
when the phagophore closes. The autophagosome fuses with the lysosome to 
form the autolysosome. Within the autolysosome, the lysosomal hydrolases 
degrade the enclosed cargo to simpler components which are finally released 
back to the cytoplasm and recycled. Adapted from “Autophagy Process”, by 
BioRender.com (2021). Retrieved from https://app.biorender.com/biorender-
templates. 
 
1.2.4 Autophagy related proteins  
The study of the molecular mechanisms involved in autophagy has been greatly 
achieved by the discovery and study of autophagy related (ATG) genes, firstly 
found in Saccharomyces cerevisiae (Yorimitsu and Klionsky, 2005; Zhao and 
Zhang, 2019; Melia et al., 2020). In Saccharomyces cerevisiae, more than 40 
ATG proteins have been identified (Table 1.1) and although there is no 
mammalian homologue for all of the yeast ATG proteins, many of them have their 






equivalent in mammals, suggesting that the autophagic machinery is highly 
conserved between these species. However, autophagy is more complex in 
mammals (Axe et al., 2008; Delorme‐ Axford and Klionsky, 2019; Zhao and 





Atg1 ULK1, ULK2 
Atg2 ATG2A, ATG2B 
Atg3 ATG3 




Atg8 LC3A, LAC3B, LC3C, GABARAP 









Atg18 WIPI1, WIPI2 
Atg19 - 
Atg20 - 






























Table 1.1 Main autophagy related proteins in yeast and mammals 
* Found in Hansenula polymorpha. **Found in Komagataella phaffii and Pichia 
Pastoris. *** Found in Schizosaccharomyces pombe (Adapted from Galluzzi et 
al, 2017; Delorme‐Axford and Klionsky, 2019; Klionsky et al., 2021) 
 
 
The ATG proteins work in complexes at specific moments to regulate the different 
steps of autophagosome formation (Figure 1.5). In mammals, the uncoordinated-
51-like kinase (ULK) complex initiates the formation of autophagosomes. Upon 
induction of autophagy in mammalian cells, this serine/threonine kinase complex 
is formed by the assembly of ULK1/2, ATG13, ATG101 and focal adhesion kinase 
family interacting protein of 200 kDa (FIP200) (Hara et al., 2008; Hosokawa et 
al., 2009a; Hosokawa et al., 2009b; Mercer et al., 2009). All components are 
conserved in Saccharomyces cerevisiae, except for ATG101. In mammalian 
cells, the function of ATG13 is to stabilize ULK1 and to target the entire ULK 
complex to the cellular region where the formation of the autophagosome occurs 
(Ganley et al., 2009; Hosokawa et al., 2009a). ATG13 and ATG101 directly 
interact with each other within the ULK1 complex, where the function of ATG101 
is the stabilization of ATG13 and ULK1 (Hosokawa, et al., 2009b). FIP200 is 
considered a scaffolding protein. Its function in the ULK complex is similar to the 
ATG13, as it is necessary to localize the complex to the autophagosome 






formation site and it also contributes to ULK1/2 stability and kinase activity 
(Ganley et al., 2009; Hara and Mizushima, 2009).  
Once the ULK complex is re-located to the autophagosome formation site, 
characterised by the presence of ATG9, it triggers the formation of class III 
phosphatidylinositol 3-kinase (PI3KC3) complex, integrated by the vacuolar 
protein sorting 34 (VPS34), BECLIN-1, VPS15 and ATG14. The activation of this 
complex is involved in the generation of phosphatidylinositol 3-phosphate (PI3P), 
a phospholipid required at the site of the biosynthesis of the autophagosome. 
PI3P drives the recruitment of additional proteins required for the formation of 
complexes involved in the completion of the autophagosome (Zeng et al., 2006; 
Russell et al., 2013; Kaur and Debnath, 2015). 
The first ubiquitin-like conjugation complex is formed by ATG16L1, ATG5 and 
ATG12, it  drives the formation of the second ubiquitin-like conjugation system. 
This second system involves the activity of ATG4,  ATG7 and ATG3. These 
systems work together to later conjugate LC3 or GABA type A receptor-
associated protein (GARABAP) to phosphatidylethanolamine (PE) into the 
expanding membrane of the phagophore (Yang and Klionsky, 2010; Cicchini et 
al., 2015; Kaur and Debnath, 2015; Bento et al., 2016; Zachari and Ganley, 2017; 
Yu et al., 2018).  
ATG9 protein plays an important role in autophagosome formation.  Up to date, 
it is the only transmembrane ATG protein that has been identified. Studies show 
that mammalian ATG9 supports the autophagosome formation by supplying 
membrane to the forming autophagosome from different sources without being 
incorporated into the autophagosome membrane (Young et al., 2006; Orsi et al., 
2012; Levine and Kroemer, 2019). 







Figure 1.5 Schematic representation of the main components of the autophagy pathway in mammals  
The core autophagy proteins involved in the autophagosome biogenesis are illustrated with their respective membrane. Activation of the 
ULK complex triggers the formation of the VPS34 complex at the site of the phagophore formation, which mediates the production of PI3P. 
PI3P recruits the components of the ubiquitin-like conjugation systems that are involved in the conjugation of LC3-II to PE and its further 
integration into the phagophore membrane. ATG9 participates in autophagosome biogenesis by aiding in the incorporation of membrane 
from different sources into the growing phagophore. The autolysosome is formed by the fusion of the mature autophagosome with the 
lysosome to degrade the enclosed contents. Created with BioRender.com. 






1.2.5 Autophagy regulation  
The study of the mechanisms that control autophagy was greatly propelled by the 
discovery of the target of rapamycin (TOR) in yeast (Heitman et al., 1991). This 
serine/threonine kinase senses and integrates the signals corresponding to the 
energy, growth and nutrient levels of the cell, and in this way is involved in the 
regulation of different cellular processes, among them autophagy (Sarbassov et 
al., 2005).  
Rapamycin, a compound produced naturally by Streptomyces hygroscopicus, 
inhibits the activity of TOR, and by doing so, it stimulates autophagy (Vézina et 
al., 1975; Sabatini et al., 1994; Brown et al., 1994). The inhibition of TOR by 
different mechanisms results in the induction of autophagy as a mechanism that 
allows the cell to respond and adapt to the changing conditions of the cellular 
environment (Neufeld, 2010).  
The mammalian homologue of the yeast TOR was later identified and is currently 
referred to as the mechanistic target of rapamycin (mTOR) (Brown et al., 1994; 
Sabatini et al., 1994; Kennedy and Lamming, 2016). mTOR is one of the 
components of 2 functional complexes: mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2). mTORC1 is highly sensitive to rapamycin while mTORC2 
is insensitive to rapamycin. Thus, the presence of rapamycin affects mTORC1 
capacity to phosphorylate downstream substrates while having no effect in the 
kinase function of mTORC2. mTORC1 is formed by the association of mTOR, 
rapamycin-associated protein of TOR (Raptor) and mLST8. mTORC2 consists of 
mTOR, mLST8, rapamycin insensitive companion of TOR (Rictor), SIN1 and 
Protor. mTORC1 is the most broadly studied of these two complexes (Kim et al., 






2002; Loewith at al., 2002; Kim et al., 2003; Guertin and Sabatini, 2007; Dunlop 
and Tee, 2014).  
Active mTORC1 is found in energy-rich and nutrient-rich conditions, this active 
state inhibits autophagy. Nevertheless, basal levels of autophagy are maintained. 
Inactivation of mTORC1 occurs under amino acid starvation conditions and 
results in the upregulation of autophagy (Dunlop and Tee, 2014). mTOR 
phosphorylates ATG13 and ULK1/2 in nutrient-rich conditions, preventing 
ULK1/2 activation (Wong et al., 2013). 
 
1.2.6 Study of autophagy  
Autophagy is frequently studied using two methodologies: the observation of the 
autophagy-specific structures and their dynamic evolution and/or the 
measurement of levels of autophagosome marker proteins and organelles as a 
function of time. Measurement of autophagy has proven to be a challenge as 
autophagy is not a static mechanism. To overcome this problem and to avoid the 
misinterpretation accompanied when analysing autophagy as a static process, 
the analysis of changes in time, representing the “autophagic flux” is preferably 
used (Yoshii and Mizushima, 2017). 
The most commonly used method to study autophagy is the analysis of the 
expression of the proteins microtubule-associated protein 1 light chain 3 (LC3) 
and p62/SQSMT1 by western blot (Bonam et al., 2020). 
LC3 was identified as a subunit of the neuronal microtubule-associated proteins 
(MAPs) MAP1A and MAP1B. The role of LC3 in the assembly and disassembly 
of microtubules was firstly thought to be its only role (Mann and Hammarback, 
1994). Subsequently, the association of LC3 to the autophagosome membrane 






was described, and its specific role on mammalian autophagy was established 
(Noda et al., 2000). LC3 is a mammalian homologue of the yeast Atg8. There are 
3 LC3 isoforms: LC3A, LC3B and LC3C. LC3B is the most commonly used for 
the study of autophagy (Noda et al., 2000; Barth et al., 2010; Mizushima et al., 
2010). Cleavage of the LC3B precursor at the C-terminal region by ATG4 after 
LC3B synthesis results in the formation of LC3B-I, which is a soluble cytosolic 
protein. Upon induction of autophagy, LC3B-I is conjugated to PE to form LC3B-
II, which mediates association of LC3B-II to the growing autophagosome 
membrane. Thus, LC3B-II has been used as a marker for the detection of 
autophagosomes (Noda et al., 2000; Tanida et al., 2005). LC3B-II is bound to 
both, the inner and outer membrane of the autophagosomes. After the formation 
of autolysosomes, the LC3B-II associated to the inner membrane is degraded 
along with the enclosed cargo while the LC3B-II bound to the outer membrane is 
delipidated and recycled (Tanida et al., 2005; Mizushima et al., 2010).  
The analysis of the levels of LC3B-I and LC3B-II is crucial for the study of 
autophagy, particularly the levels of LC3B-II turnover. The identification of these 
two different LC3B forms by Western blotting technique is based on their different 
migration pattern on SDS-PAGE. Even though the molecular weight of the 
lipidated form LC3B-II is higher than the soluble LC3B-I form, LC3B-II migrates 
faster than LC3B-I. The faster mobility of LC3B-II is due to the increased 
hydrophobicity given by its conjugation to PE. Thus, in SDS-PAGE the apparent 
molecular weight of LC3B-I is 16 kDa and the apparent molecular weight of LC3B-
II is 14 kDa (Barth et al., 2010; Mizushima et al., 2010). 
Nevertheless, the levels of LC3B-I and LC3B-II by themselves cannot be used to 
describe autophagic flux at a specific time point. An increase in LC3B-II levels 






could be caused by two different scenarios. In scenario one, the increase in the 
levels of LC3B-II reflects an increase in autophagosome number as a result of an 
increase in autophagic activity. In scenario two, the increase of LC3B-II occurs 
because of the accumulation of autophagosomes that cannot be degraded. To 
be able to distinguish between these two (and opposing) alternatives, the 
measurement of LC3B-II levels must be carried out in the presence and absence 
of lysosomal inhibitors, such as Bafilomycin A1 (BafA1), that prevents 
downstream clearance of autophagosomes (Figure 1.6) (Yoshii and Mizushima, 
2017). 
 
Figure 1.6 Diagram of Western blot showing changes in LC3B marker in the 
presence and absence of lysosomal inhibitor under control and treatment 
conditions 
Presence of Baf A1 in the control condition results in an increase in the protein 
levels of LC3B-II, while the presence of Baf A1 in the treatment condition results 
in: A. further increase in LC3B-II levels indicating an autophagic flux increase, or 
B. does not result in changes of LC3B-II levels indicating inhibition of the 
autophagic flux. Created with BioRender.com. 







The ratio of LC3B-II/LC3B-I is no longer commonly used as a measurement for 
autophagic flux, as most of the antibodies available commercially have more 
affinity to LC3B-II, masking the amount of LC3B-I present. Secondly, because 
LC3B-I expression in Western blotting varies depending of the cell line, and in 
some cell lines the LC3B-I band is very faint or cannot be detected (Yoshii and 
Mizushima, 2017). 
p62, also known as sequestosome 1 (SQSTM1) in humans, is an adaptor protein 
that targets polyubiquitinated substrates for degradation via autophagy and/or via 
the proteasomal pathway (Seibenhener et al., 2004; Kirkin et al., 2009). p62 binds 
to ubiquitin in a non-covalent manner (Vadlamudi et al., 1996), its C-terminal 
region contains an ubiquitin-associated (UBA) domain that is required for its 
interaction with the polyubiquitinated substrates. On its N-terminal region, p62 
has a Phox and Bem1p (PB1) domain that functions as an ubiquitin-like (UBL) 
domain. The PB1 domain is required for its interaction with the proteasome and 
thus, for the delivery of the ubiquitinated substrates for proteasomal degradation 
(Seibenhener et al., 2004; Bjørkøy et al., 2005; Isogai et al., 2011; Cohen-Kaplan 
et al., 2016). p62 also contains an LC3 interaction region (LIR) that mediates the 
interaction with LC3 (Pankiv et al., 2007). The direct interaction between p62 and 
LC3B in the autophagic vesicles is responsible for the trapping and degradation 
of p62 alongside the engulfed cargo during autophagy (Bjørkøy et al., 2005; 
Pankiv et al., T. 2007). Therefore, accumulation of p62 typically indicates the 
inhibition of autophagy and as such, the analysis of p62 levels is widely used to 
study autophagic flux (Pankiv et al., 2007). 






It is important to emphasise that p62 plays a role in the two major pathways of 
protein degradation (autophagy and proteasomal degradation), and therefore 
cannot be used by itself to describe autophagic flux (Mizushima et al., 2010). The 
ubiquitin-proteasome mechanism is used for the degradation of misfolded, non-
functioning proteins as well as short lived proteins. Before proteasomal 
degradation occurs, these type of proteins are tagged with Lys-48 polyubiquitin 
chains and transported by Ub-binding receptors, including p62, to the 
proteasome for degradation (Glickman and Ciechanover, 2002; Pankiv et al., 
2007; Kirkin et al., 2009). The second degradation machinery in which p62 plays 
a role is autophagy. Autophagy is activated to degrade protein aggregates, long-
lived proteins and defective organelles, among other substrates. p62 sequesters 
polyubiquitinated protein aggregates too large to fit into the proteasomal cavity 
and delivers them to the autophagic vesicles for selective degradation (Bjørkøy 
et al., 2005; Pankiv et al., 2007; Cohen-Kaplan et al., 2016). 
 
1.2.7 Regulation of autophagic flux by interaction between ATG101 
and the C-terminal domain of PTCH1.  
With the objective of identifying specific CTD-interacting proteins, a yeast-two-
hybrid screening was carried out by past members of the Dr. Riobo Del-Galdo 
team. One of the retrieved cDNA clones encoded for ATG101, an autophagy 
related protein that is essential for the initiation of autophagy in mammalian cells. 
As previously mentioned, ATG101 is one of the members of the ULK complex, 
that has a nutrient sensing activity and is known as the autophagy initiation 
complex (Hosokawa et al., 2009a; Hosokawa et al., 2009b; Ganley et al., 2009). 
By interacting with ATG101, the CTD of PTCH1 mediates a blockade of the basal 






and amino acid starvation-induced (via mTORC1) autophagic flux at a step 
downstream of the action of the ULK complex (Chen et al., 2018). 
 
1.3 ITM2A 
The Integral Membrane protein 2A (ITM2A) gene was identified for the first time 
using a cDNA library of in-vitro cultivated condyles from mouse mandible in a 
study designed to find new markers for chondro-osteogenic differentiation 
(Deleersnijder et al., 1996). ITM2A is part of the type II Integral Membrane protein 
(ITM2) family and the BRICHOS superfamily. The ITM2 family does not share 
structural characteristic associated with other known protein families and it 
comprises three members: ITM2A, ITM2B and ITM2C (Deleersnijder et al., 1996; 
Van den Plas and Merregaert, 2004a; Kihara et al., 2014). ITM2A is a 263 amino 
acids protein and contains a single putative transmembrane domain at 54-74 
amino acids (UniProtKB ID: O43736). ITM2A is classified as a type II integral 
membrane protein as it has an extracellular C-terminus and an intracellular N-
terminus. This topology is congruent with its only N-glycosylation site at Asn-166 
(Deleersnijder et al., 1996; Kirchner and Bevan, 1999). ITM2A contains a 
BRICHOS domain in the extracellular region at amino acids 133-227 (Kihara et 
al., 2014; Tai et al., 2014). The BRICHOS domain is found in some proteins that 
have been linked to dementia, respiratory problems or different types of cancer. 
The BRICHOS domain, of approximately 100 amino acids-long, is believed to 
have an intramolecular chaperone function (Sánchez-Pulido et al., 2002).  
The protein sequence of ITM2A, ITM2B and ITM2C is highly conserved between 
human and mouse. The percentage of homology between these species is, for 
ITM2A: 94.7%, for ITM2B: 95.5%, and for ITM2C: 92.9%. However, the homology 






among the three members in the same species is only around 40%. Human 
ITM2A is only 38% identical to human ITM2B and 42.1% identical to human 
ITM2C, while human ITM2C shares 49.5% identity with human ITM2B. Among 
the different members of the ITM2 family, the N-terminus is the most variable 
region and the extracellular C-terminal part is the most conserved one 
(Deleersnijder et al., 1996; Choi et al., 2001). ITM2 family protein members are 
expressed in different tissues, and only few tissues, such as the brain, co-express 
all three members (Deleersnijder et al., 1996). ITM2A is highly expressed in 
skeletal muscle, in the growth plate of long bones and in the thymus, in all of 
which the Hh pathway plays an important development role. ITM2A expression 
has also been detected in mature osteoblasts, mature odontoblasts, 
chondrocytes and T cells (Kirchner and Bevan, 1999; Tuckermann et al., 2000; 
Kihara et al., 2014). ITM2A is expressed in endochondral bone-derived structures 
such as ribs and vertebra (Van den Plas and Merregaert, 2004b), and in the foetal 
heart, brain and  skin. In situ hybridization showed the presence of ITM2A in adult 
brain, renal cortex and small intestine (Choi et al., 2001). Lower expression levels 
of ITM2A are found in the lymph nodes, spleen, heart, lungs, stomach and uterus 
(Kirchner and Bevan, 1999). ITM2B is ubiquitously expressed in adult tissues and 
in several neonatal tissues and ITM2C was found in higher levels in brain tissue 
(Choi et al., 2001).  
The EL4 murine thymoma cell line was used to study the subcellular localisation 
of Itm2a. Results showed that Itm2a is located at the plasma membrane as well 
as in intracellular vesicles, and potentially in endosomes and the Golgi apparatus. 
(Kirchner and Bevan, 1999). Using the EL4 cell line, it was also shown that the 
endogenous expression levels of Itm2a are highly variable in single cells, ranging 






from no expression to high expression. More studies are required to fully 
understand its cellular localisation and patterns of expression at an mRNA and 
protein level (Kirchner and Bevan, 1999). 
Studies carried out by different groups show that the PKA-CREB (protein kinase 
A-cAMP responsive element binding protein), PAX3 and GATA-3 play key roles 
in the regulation of ITM2A expression (Namkoong et al., 2015; Nguyen et al., 
2016).  
Although ITM2A plays a role in cell differentiation, its effects are cell type specific. 
There are reports of its involvement in chrondrogenesis, odontogenesis and 
myogenesis as well as in autoimmune disorders. However, its molecular function 
has not been fully elucidated (Kihara et al., 2014; Nguyen et al., 2016; Zhou et 
al., 2019). A recent article suggested that ITM2A plays a negative role in 
autophagy through an inhibitory interaction with V-ATPase, which acidifies the 
autolysosomes. Overexpression of ITM2A in HEK293 and HeLa cells resulted in 
a block of the autophagic flux which generated an accumulation of 
autophagosomes that could not be degraded. This study suggests that the 
interaction of ITM2A with V-ATPase inhibits the acidification of the autophagic 
vesicles and also that this interaction is involved in the suppression of the 
formation of autolysosomes (Namkoong et al., 2015). 
Recent studies show that changes in the expression of ITM2A are linked to breast 
and ovarian cancer (Nguyen et al., 2016; Zhou et al., 2019). Expression of ITM2A 
is downregulated in different breast cancer cell lines, while overexpression of 
ITM2A inhibited the proliferation of breast cancer cells. Published results show 
that there is a correlation between low levels of ITM2A expression and poor 
outcomes for breast cancer patients, as well as lower survival rate in specific 






types of breast cancer (HER2+). The study of the role of ITM2A in breast cancer 
supports a different role of ITM2A in autophagy. The study showed that ITM2A 
stimulates autophagy by inhibiting the activation of mTOR in breast cancer cell 
lines (SKBR-3 and MDA-MB-231), as opposed to the inhibitory effect in HEK293 
and HeLa cells described earlier (Namkoong et al., 2015). Overexpression of 
ITM2A inhibited 4EBP1 phosphorylation (a readout of mTOR activity), which 
resulted in decreased cell proliferation, decreased growth and reduced colony 
formation in breast cancer cells. Interestingly, the study shows the requirement 
of T35 phosphorylation in ITM2A by the protein kinase HUNK for this effect, 
suggesting that differential HUNK expression or activity in different cell types 
could account for the opposite findings (Zhou et al., 2019). 
A different study showed that ITM2A acts as a tumour suppressor also in 
epithelial ovarian cancer. ITM2A is downregulated in ovarian cancer cell lines  
and in ovarian cancer tissues, particularly in invasive ovarian carcinomas. Loss 
of  ITM2A expression was linked to an increase in resistance to chemotherapy 
treatment and cancer recurrence. Furthermore, ITM2A overexpression produced 
a decrease in cell growth in ovarian cells by promoting cell cycle arrest in the 
G2/M phase. Studies in animal models showed that the expression of ITM2A 
contributed to the reduction of tumour growth. This study suggests that 
downregulation of ITM2A expression hinders the G2 checkpoint, which causes 
an increase in cell proliferation  (Nguyen et al., 2016). 
 
1.4 Cell cycle  
The cell cycle is a complex process that orchestrates DNA replication and cell 
division following upstream cues that are involved in the monitoring and 






regulation of cell growth, and also signals from different proteins that assess DNA 
damage (Otto and Sicinski, 2017). Cellular proliferation is the result of the 
completion of the different phases of the cell cycle. The cell cycle is divided in 
four phases: Gap 1 (G1), DNA synthesis (S), Gap 2 (G2) and mitosis (M) (Gautier 
et al., 1988). During the gap phases G1 and G2, cells undergo control checks to 
evaluate if the cells are ready to progress into the next step of the cell cycle and 
to prepare for the following phase, S phase or M phase, respectively. During S 
phase, nuclear DNA is duplicated and during the M phase mitosis occurs to 
generate two daughter cells (Norbury and Nurse, 1992; Schafer, 1998). The G0 
phase, often referred to as “quiescence”, is a resting state that can be permanent 
or transitory. Most of the cells that are not dividing in adult tissues are found in 
G0 phase in one of two different ways: they can be quiescent, which is a transient 
state, meaning that cells can be induced to return to the cell cycle given the right 
stimulation, for example exposure to mitogens. G0 phase also includes 
senescent and terminally differentiated cells, which are permanent states (Otto 
and Sicinski, 2017). The check-points in the cell cycle are crucial for the 
maintenance of cellular integrity as they function to avoid uncontrolled 
proliferation and duplication of damaged or mutated DNA (Thu et al., 2018). In 
mammalian cells, there is also a point known as the restriction point, it occurs in 
late G1 phase. In this point, the cells integrate external signals before irreversible 
committing to DNA replication (Hunter and Pines, 1994). 
 
1.4.1 Cyclin dependent kinases and cyclins  
The eukaryotic cell cycle is regulated by a family of threonine/serine proteins 
known collectively as cyclin-dependent kinases (CDKs). The activation and 






inactivation of the CDKs is regulated by the formation of different complexes with 
proteins that are expressed specifically during certain phases of the cell cycle, 
called cyclins. Cyclins function as the regulatory subunits of the CDKs and the 
interaction between these two proteins is essential for the activity of the CDKs 
(Luedde et al., 2003; Otto and Sicinski, 2017;). In a similar manner, the 
inactivation of CDKs is mediated by their interaction with CDK inhibitors (CDKIs) 
(Franklin and Xiong, 1996).  
Cyclins are the limiting factor for the formation of the CDK-cyclin complexes. 
While the protein levels of the CDKs are maintained relatively constant during the 
cell cycle, the level of cyclins changes during the different phases. The activation 
of the different CDK complexes, as a response of cyclin’s presence is what drives 
the cell cycle progression (Vermeulen et al., 2003; Malumbres, 2014). The CDKs 
that play key roles in the regulation of the cell cycle are: CDK2, CDK4, CDK6 and 
CDK1 also known as cell division control protein 2 (CDC2). The cyclins involved 
in cell cycle progression include: A-type, B-type, D-type and E-type cyclins 
(Malumbres and Barbacid, 2009).  
CDK4 and CDK6 share a high degree of homology and are involved in the 
process that drives the re-entering of G0 arrested cells into the G1 phase of the 
cell cycle and also in the cell progression through the early G1 phase. Studies 
have shown that these two kinases share the same function in many tissues, 
having some degree of redundancy (Anders et al., 2011; Otto and Sicinski, 2017). 
CDK4 and CDK6 form complexes with D-type cyclins: cyclin D1, cyclin D2 and 
cyclin D3. Interaction with D-type cyclins drives the activation of these CDKs 
(Sherr and Roberts, 1999; Luedde et al., 2003). D-type cyclins are not 
synthesised and degraded depending on the cell cycle phase, instead they are 






expressed in response of the presence of extracellular growth factors (Assoian 
and Zhu, 1997; Vermeulen et al., 2003). Once these CKDs are activated, they 
are able to exert their function and phosphorylate their substrate: retinoblastoma 
tumour suppressor protein (Rb). Phosphorylated (pRb) is inactive (Pines, 1995; 
Vermeulen et al., 2003). The complex formed by CDK4/6 and a D-type cyclin 
phosphorylates Rb in mid to late G1 phase, which leads to the synthesis of 
proteins involved in the following phases of the cell cycle, such as cyclin A and 
cyclin E (Pines, 1995; Vermeulen et al., 2003). The activation of CDK2 by cyclin 
E is the next complex to be formed and is required for the progression of the G1 
phase and to drive the transition to S phase. This complex plays a role in the 
maintenance of the hyperphosphorylated state of pRb, which is required until the 
early M phase. Next in the progression of the cell cycle, the complex CDK2-cyclin 
A is needed for completion of S phase. The complex formed by CDK1 and cyclin 
A is required for the transition from G2 to M phase, while the formation of the 
complex CDK1-cyclin B is required for M phase (Vermeulen et al., 2003). 
 
1.4.2 CDK inhibitors  
The regulation of CDKs and CDK-cyclin complexes is mediated by their 
interaction with CDKIs. Two different families of CDKIs have been described: The 
INK4 family and the Cip/Kip family (Pines, 1995; Vermeulen et al., 2003). The 
INK4 family of inhibitors forms complexes with CDK4 and CDK6 exclusively, and 
is composed of p16INK4A, p15INKB, p18INK4C and p19INK4D. Inhibitors from the INK4 
family exert their inhibitory function by binding to the CDKs, blocking in this way 
the interaction of CDK4 and CDK6 with D-type cyclins. The inactivation of the 
CDK4/6 by INK4 family of inhibitors prevents the phosphorylation of the target 






substrates, such as Rb (Sherr and Roberts, 1999; Luedde et al., 2003). The other 
family of CDKIs is the Cip/Kip family, that contains three inhibitor proteins: 
p21CIP1/WAF1, p27KIP1 and p57KIP2, which can interact with most CDKs. The Cip/Kip 
family of inhibitors exert their activity by interacting with the cyclins in the already 
formed CDK-cyclin complex (Schafer, 1998; Sherr and Roberts, 1999).  
 
1.4.3 Differentiation 
Eukaryotic cells that undergo differentiation are required to exit the cell cycle. 
Different studies show that the regulation of D-type cyclins expression and of Rb 
phosphorylation are key for differentiation (Pines, 1995). There is evidence that 
the decision to stop proliferating and start the differentiation process, occurs 
during the early G1 phase (Kiyokawa et al., 1994). A study carried out in murine 
erythroleukemia (MEL) cells that were induced to differentiate, suggests that the 
commitment to differentiation takes place in G1 phase as a response of a 
decrease in the levels of CDK4. Downregulation of CDK4 was related to a 
decrease in the stability of the protein, by a higher rate of degradation. Therefore, 
there was a decrease in the formation of the complex CDK4-cyclin D, which 
generated the accumulation of hypophosphorylated Rb, although an amount of 
phosphorylated pRb remained. In this study, an increase in cyclin D3 was also 
observed. Cyclin D3 formed a complex directly with hypophosphorylated Rb. 
These changes potentially induce the withdrawal from the cell cycle and 
commitment to differentiate in MEL cells (Kiyokawa et al., 1994).  
It has been suggested that the downregulation of cyclin D1 is required for the 
initiation of myogenic differentiation. Overexpression of cyclin D1, blocks 
myogenic differentiation and promotes the maintenance of the proliferative state. 






Different studies show that during myogenic differentiation, the expression 
pattern of the different D-type cyclins is varied. The levels of cyclin D1 are 
downregulated and become almost undetectable in myotubes. On the contrary, 
levels of cyclin D3 are upregulated upon induction of differentiation, and higher 
levels of cyclin D3 are detected in myotubes. The decrease on cyclin D1 as well 
as the increase in cyclin D3 is accompanied by the accumulation of 
hypophosphorylated Rb and most of the Rb detected in myotubes was found in 
hypophosphorylated state. (Rao et al., 1994; Skapek et al., 1995; Bartkova et al., 
1998).  
Withdrawal from the cell cycle is an important step for differentiation. Studies 
suggest that upregulation of p21 is required for myoblasts to exit the cell cycle on 
G1 phase and enter G0 phase to start myogenic differentiation (Halevy et al., 
1995; Parker et al., 1995; Skapek et al., 1995; Duronio and Xiong, 2013).  
Alongside cell cycle withdrawal, the induction of myogenic differentiation is 
accompanied by the expression of muscle specific genes, whose expression is 
regulated by the activity of the MyoD family of skeletal muscle specific basic helix-
loop-helix (bHLH) transcription factors also known as the myogenic regulatory 
factors (MRFs) family (Lassar et al., 1994; Hernández-Hernández et al., 2017).  
The MRF family is composed of 4 members: MyoD, myogenin, Myf-5 and MRF4. 
Proliferating myoblasts express MyoD and Myf-5, myogenin is expressed in 
differentiating cells while MRF4 is expressed in terminally differentiated 
myotubes. MyoD orchestrates different events that induce the expression of 
myogenin, which also causes the downregulation of Myf-5. The expression of 
myogenin marks the myoblast commitment to differentiation and is accompanied 
by withdrawal of the cell cycle. During differentiation, the expression of MyoD and 






myogenin is involved in the regulation of the expression of MRF4, among other 
muscle-specific proteins. Differentiated myotubes are characterised by a 
decrease in the levels of MyoD and myogenin while the expression of MRF4 is 
maintained (Skapek et al., 1995; Hernández-Hernández et al., 2017). 
Studies suggest that the regulation of the MRF family proteins is linked to the 
expression of components of the cell cycle. Expression of cyclin D1 inhibits the 
MRF family. When myoblasts are subjected to reduced mitogen environment, 
such as the one created in vitro by switching to media with 2% horse serum, they 
undergo cell cycle arrest while the MRF family mediates the transcription of 
muscle genes (Rao et al., 1994; Skapek et al., 1995). 
Therefore, myogenic differentiation of skeletal muscle cells can be separated in 
four consecutive steps that start, upon differentiation induction, with the 
expression of myogenin (potentially regulated by the changes in the expression 
of cell cycle proteins). Next is the cell cycle exit, driven by the upregulation of p21 
and cyclin D3 expression, which is followed by the induction of muscle-specific 
proteins such as Myosin Heavy Chain (MHC), which leads to the final step, cell 
fusion, that results in differentiated multinucleated myotubes (Walsh and 
Perlman, 1997; Gurung and Parnaik, 2012). 
 
1.5 Outline of doctoral research  
The Hh signalling pathway plays a crucial role during embryonic development, it 
is also involved in the regeneration of adult tissues. Dysregulation of the Hh 
signalling pathway has been associated with different diseases including cancer 
(McMahon et al., 2003; Petrova and Joyner, 2014; Bangs and Anderson, 2017). 
The Hh receptor PTCH1 is a well-established tumour suppressor that, in an 






unbound state, represses the activation of SMO, which results in the generation 
of Gli2 and Gli3 repressor forms. Binding of any of the Hh ligands to PTCH1 
relieves the repression of SMO, which results in the processing of the Gli activator 
forms that translocate to the nucleus and activate the Hh target genes expression 
(Yang et al., 2015). The non-canonical Hh signalling have been described in 
recent years, it does not involve the activation of the Gli family of transcription 
factors. Type I non-canonical Hh signalling includes the processes that are 
dependent of PTCH1 and independent of SMO activation. Type II non-canonical 
Hh signalling is dependent of SMO and independent of the activation of the Gli 
proteins (Brennan et al., 2012).  
Studies show that the CTD of PTCH1 is not involved in the regulation of the 
canonical Hh signalling pathway, while it is required for PTCH1 localisation and 
turnover. The CTD is also involved in the pro-apoptotic function of PTCH1 
(Thibert et al., 2003; Lu et al., 2006; Fleet et al., 2016). Previous members of our 
lab carried out a yeast-two-hybrid screening to identify new CTD-interacting 
proteins. One of the proteins identified was ATG101. Our study showed that the 
effect of the interaction between PTCH1 and ATG101 occurs at the final step of 
autophagy and results in the accumulation of autophagosomes that cannot be 
degraded, causing an inhibition of the autophagic flux (Chen et al., 2018). 
Considering that ATG101 is involved in the initiation of autophagy, one of the 
main aims of my doctoral research was to understand this protein interaction by 
investigating the functional consequences of three somatic mutations found in the 
CTD in human cancer databases. We hypothesised that losing the interaction in 
any of the cancer mutants could have consequences in the autophagic flux 
blockade induced by PTCH1, which could give cancer cells a growth advantage. 






These results are relevant as they strengthen the hypothesis that the tumour 
suppressor role of PTCH1 is not only given by its function as SMO repressor, but 
also independently of it following a type I non-canonical Hh signalling (Chen et 
al., 2018).  
Considering that ATG101 is involved in the initiation of autophagy and no role of 
ATG101 in the final steps of autophagy have been described, we first 
hypothesised that the autophagic flux blockade induced by PTCH1 might involve 
the interaction of PTCH1 with other proteins. Therefore, the second part of my 
research had the aim to validate and characterise the interaction between ITM2A 
and PTCH1. ITM2A is a type II membrane protein that inhibits autophagic flux at 
the final step of the process thorough interaction with V-ATPase (Deleersnijder 
et al., 1996; Namkoong et  al., 2015). In addition, ITM2A was also identified by 
our group in the yeast-two-hybrid screening as a potential CTD interacting 
protein. Therefore, we first hypothesised that ITM2A was a mediator of the 
autophagic flux blockade regulated by PTCH1. However, our findings showed 
that both, ITM2A and PTCH1, inhibit autophagic flux independently of their 
interaction.  
Different studies show that ITM2A is involved in myogenic differentiation of 
C2C12 cells. ITM2A levels increase during myogenic differentiation of C2C12 
cells while higher levels of ITM2A are related to a faster formation of myotubes 
(Van den Plas and Merregaert, 2004a; Lagha et al., 2013). Of importance, 
canonical Hh signalling pathway promotes proliferation of C2C12 cells, and in this 
way prevents myogenic differentiation of C2C12 (Koleva et al., 2005). Therefore, 
we aimed to investigate the crosstalk of ITM2A with Hh canonical pathway. 
Considering this, and the results throughout this research we hypothesised that 









































Chapter 2                                                                        
Materials and Methods  
2.1 Cell culture 
HEK293, HEK293T, HeLa, NIH3T3 and C2C12 cell lines were obtained from 
American Type Culture Collection (ATCC). Ptc1+/- and Ptc1-/- mouse embryonic 
fibroblasts (MEFs) were a gift from Dr. Matthew Scott (Stanford University). Table 
2.1 shows the general information of the used cell lines. All cell lines were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM, high glucose) 
(Gibco), supplemented with 10% Foetal Bovine Serum (FBS) (Gibco, D6546) and 
GlutaMAXTM (Gibco). Cell lines were cultured at 37°C and 5% CO2 atmosphere 
in a humidified incubator. For passaging, cell media was removed and cells were 
washed with 2 ml of 1x PBS and detached with 2 ml of Trypsin-EDTA solution 
0.25% (Merk Life Science UK Limited) for approximately 5 minutes. Cells were 
diluted with 8ml of fresh pre-warmed growth media and then seeded at the 
desired cell density.  HEK293, HEK293T and HeLa cell lines were passaged upon 
reaching approximately 80-90% confluence at usual dilutions of 1:20, 1:10 and 
1:5 as required. C2C12, NIH3T3 and MEFs were subcultured before reaching 
80% confluence at usual concentrations of 1:20, 1:10 and 1:5 as required.  
shITM2A and shScramble HEK293, HeLa and C2C12 with were generated in-
house as described later in this chapter. They were maintained in the same 
parental growth media with the addition of puromycin at the specified 










Cell line Organism Cell type Tissue Properties/Disease 
HEK293 Human Epithelial Embryonic 
kidney 
Adherent 
HEK293T Human Epithelial Embryonic 
kidney 
Adherent 
HeLa Human Epithelial Cervix Adherent/ 
Adenocarcinoma 
NIH3T3 Mouse Fibroblast Embryo Adherent 





Mouse Fibroblast Embryo Adherent 
Table 2.1 Cell lines used for cell biology experiments 
Main characteristics of the cell lines used for cell culture.  
 
 
2.2 Long-term storage and recovery of cell lines 
Cryogenic storage in liquid nitrogen was used for long-term storage of cell lines. 
To prepare the cell stocks, cells were grown to confluence in a 10 cm dish (except 
NIH3T3, C2C12 and MEFs that were grown to 70% confluence), washed with 2 
ml of 1x PBS, detached with 2 ml of trypsin-EDTA and diluted with 8 ml of fresh 
growth media. Cells were centrifuged for 4 minutes at 4000 RPM, the obtained 
cell pellet was re-suspended in 3 ml of freezing media (10% DMSO (Sigma) in 
FBS) and aliquoted into 1 ml cryotubes. Cryotubes were placed in a Mr. Frosty 
freezing container (Nalgene) filled with isopropanol and frozen overnight at -80°C. 
Cryotubes were then stored in the liquid nitrogen dewar.  
To thaw cells, cryovials were retrieved from the liquid nitrogen dewar and placed 
immediately into dry ice, and from dry ice, directly into the water bath or bead 
bath at 37°C. Once thawed, the entire content (1 ml) of the vial was transferred 
into a culture flask containing 9 ml of pre-warmed growth media. Cells were then 
incubated at 37°C and 5% CO2 and monitored for recovery.   






2.3 C2C12 myoblast differentiation into myotubes  
C2C12 proliferating myoblasts were seeded in 6-well plates (unless otherwise 
specified) using growth medium at a concentration of 200,000 cells/ml to reach 
confluence after 24 hours of seeding. Upon reaching 100% confluency, cells were 
washed twice with 2 ml of 1x PBS and switched to pre-warmed differentiation 
media: DMEM supplemented with 2% horse serum (Merk Life Science UK 
Limited) and 1% GlutaMAXTM. Cells were maintained in differentiation media for 
7 days, fresh media was changed every other day. Morphology of C2C12 during 
differentiation was monitored and documented using an EVOS® FL Auto Cell 
Imaging System (Thermo Fisher). 
 
2.4 Cell counting  
Cells were quantified manually using a haemocytometer chamber. Briefly, cells 
were trypsinised and diluted in growth media, 10 µl of the cell mix were placed in 
the haemocytometer chamber and counted using an inverted microscope. Under 
the microscope the haemocytometer is divided into 4 quadrants. The cells within 
those quadrants, as well as the cells in the top and right edge were considered in 
the quantification. The total number obtained was divided by 4 and multiplied by 
10,000 to obtain the number of cells per ml. Cells were then diluted and seeded 
depending on the cell type and the experiment planned.  
To obtain the cell doubling rate of the generated cell lines with silenced ITM2A, 
cell counting was carried out as above at time points 0, 24, 48 and 72 hours. The 
number of cells seeded (0 hours) varied depending on the cell line. For HEK293, 
75,000 cell/ml were seeded. For HeLa and C2C12, the seeding number was 
50,000 cells/ml.  






2.5 Transient transfection 
Unless otherwise specified, transient transfection was carried out using 
transfection reagent LipofectamineTM 2000 (Thermo Fisher Scientific). Cells were 
plated in 6-well plates in antibiotic-free growth medium at the following densities: 
3 x 105 cells/ml for HEK293, 1.5 x 105 cells/ml for HeLa cells,  and  7.5 x 104 
cells/ml for C2C12 cells. The following volumes correspond to a 6-well plate size 
configuration, while Table 2.2 shows the volumes for different plate sizes. Briefly, 
250 µl of Opti-MEM® (Thermo Fisher Scientific) were mixed with 4 µg (total) of 
DNA plasmid or combination of plasmids and mixed gently by pipetting up and 
down. In a second Eppendorf tube, 10 µl of LipofectamineTM 2000 were added 
directly into 250 µl of Opti-MEM®, mixed gently and incubated for 5 minutes at 
room temperature. To obtain a transfection reagent:DNA (µl:µg) ratio of 2.5:1, 
250 µl of the mix Opti-MEM®/LipofectamineTM 2000 were added to the mix of Opti-
MEM®/DNA and incubated for 30 minutes at room temperature. The entire mix 
Opti-MEM®/LipofectamineTM 2000/DNA  was added dropwise to each well. Cells 
were incubated overnight at 37°C and 5% CO2 and media was replaced by fresh 
growth media before any other assay.  
 
Plate type DNA (µg) Opti-MEM® (µl) LipofectamineTM 2000 (µl) 
24-well  1 125 2.5 
12-well 2 250 5 
6-well 4 500 10 
Table 2.2 Total volume of components required for transient transfection 
 
2.6 siRNA transfection  
HEK293 and HeLa cells were transfected in 10 cm culture dishes following the 
reverse transfection protocol using the transfection reagent LipofectamineTM 






RNAiMAX (Invitrogen) using human ITM2A siRNA (Santa Cruz Biotechnology) 
and MISSION siRNA negative control (Sigma). For HEK293 160 pmol of siRNA 
was used and for Hela cells 80 pmol of siRNA was used. Briefly, for each 
transfection the ITM2A siRNA was diluted into 2 ml of Opti-MEM® directly in the 
culture dish and mixed gently. Then LipofectamineTM RNAiMAX was added to the 
dish containing the siRNA (20 µl for HEK293 and 16 µl for HeLa), mixed gently 
and incubated for 10 minutes at room temperature. Per transfection reaction, 
HEK293 cells were diluted in 10 ml of growth media at a density of 3.5 x 105 
cells/ml and HeLa cells were diluted in 10 ml of growth media at a density of 1.5 
x 105 cells/ml. After incubation time, diluted cells were added to the dish 
containing the combined siRNA and RNAiMAX in Opti-MEM®, mixed gently and 
incubated overnight at 37°C and 5% CO2. 24 after reverse transfection, cells were 
tripsinised and seeded in 12-well plate at the following densities (1 ml/well):  
HEK293 cells were seeded at 4 x 105 cells/ml and HeLa cells were seeded at a 
density of 2 x 105 cells/ml and incubated overnight at 37°C and 5% CO2. 24 hours 
after seeding, cells were transiently transfected with PTCH1-HA or pcDNA3.1 
using LipofectamineTM 2000 as described earlier in this chapter and incubated 
overnight at 37°C and 5% CO2. 4 hours before lysis and RNA extraction, cells 
were treated with Bafilomycin A1 as established later in section 2.12, for a total 
of  72 hours after siRNA transfection and 24 hours of PTCH1-HA transfection. 
 
2.7 Puromycin killing curve  
For cell lines HEK293, HeLa and C2C12, a puromycin (Cayman Chemicals) 
killing curve was performed to obtain the optimal concentration of antibiotic to be 
used for selection. For a 6-well plate HEK293 cells were seeded at a 






concentration of 3 x 105 cells/ml, HeLa cells and C2C12 myoblasts were seed at 
a concentration of 1 x 105 cell/ml. 24 hours after seeding, each well was treated 
with different concentrations of puromycin: 0-2.5 µg/ml (in 0.5 µg/ml increments). 
Viability of the cells was examined every two days for 2 weeks, changing to 
puromycin-containing fresh growth media every 3 days. The chosen puromycin 
concentration corresponds to the lowest concentration that starts causing 
massive cell death by day 3 and that kills all the cells within 2 weeks. For HEK293 
and HeLa cells the concentration was 1.5 µg/ml and for C2C12 the concentration 
was 2 µg/ml.  
 
2.8 Transfection of shRNA  
ITM2A shRNA plasmid human (Santa Cruz Biotechnology, sc-60867-SH) was 
used for transfection in HeLa cells and HEK293 cells. Itm2a shRNA plasmid 
mouse (Santa Cruz Biotechnology, sc-60868-SH) was used for transfection of 
C2C12 cells. Control shRNA Plasmid A (Santa Cruz Biotechnology, sc-108060) 
was used as negative control. For a 6-well plate, HEK293 cells were seeded at a 
concentration of 2 x 105 cells/ml, HeLa cells were seed at a concentration of 1 x 
105 cell/ml and C2C12 myoblasts were seed at a concentration of 5 x 104 cell/ml. 
For each transfection reaction, 1 µg of shRNA was mixed with 250 µl of Opti-
MEM®. In a second microcentrifuge tube, 250 µl of Opti-MEM® were mixed with 
4µl of LipofectamineTM 2000 and incubated for 5 minutes at room temperature. 
The solution containing the shRNA-encoding plasmid was added to the solution 
containing the transfection reagent, gently mixed by pipetting up and down and 
incubated 30 minutes at room temperature. After incubation, cells were washed 
with 2 ml of 1x PBS, next 2 ml of pre-warmed Opti-MEM® were added into each 






well followed by the addition of the transfection reaction. Cells were incubated at 
37°C and 5% CO2 for 5 hours. Media was removed and cells washed with 1x 
PBS, 2 ml of pre-warmed Opti-MEM® with 10% FBS were added to each well and 
cells were incubated for 24 hours before starting selection of stably transfected 
cells with puromycin.  
 
2.9 Isolation of single cell-derived clones  
To isolate single clones from the shRNA stably transfected cell pool, the limiting 
dilution technique was used. Cells were counted using the haemocytometer as 
described previously (section 2.4) and seeded in a 96-well plate at a density of 5 
cells/ml (100 µl/well), and left undisturbed for 2 weeks. Colonies growing from 
individual wells containing 1 cell were expanded in 24-well plate, followed by 6-
well plate and T75 flasks using selective growth media. 
 
2.10 Lentivirus particle generation  
The HEK293T cell line was used for the generation of replication-incompetent 
lentiviruses. Briefly, cells were seeded in a T25 flask at a confluence of 1.5 x 105 
cells/ml (5 ml) to reach a confluence of ~60% 24 hours after seeding. For each 
transfection reaction 2 µg of psPAX2 packing vector, 2 µg of pVSV-G envelope 
vector and 3.5 µg of shRNA encoding vector were added into a microcentrifuge 
tube. Next, 500 µl of Opti-MEM® were added to the DNA mix followed by the 
addition of 22.5 µl of TransIT-LT1 (Mirus) directly into the Opti-MEM®/DNA mix 
(transfection reagent volume/µg DNA ratio= 3:1). Transfection reaction was 
mixed gently by flicking the tube, incubated for 15 minutes at room temperature 
and added dropwise to the culture flask. Cells were incubated at 37°C and 5% 






CO2 for 5 hours. Media was then aspirated and replaced with fresh growth media, 
cells were incubated at 37°C and 5% CO2 overnight. Virus-containing 
supernatant was collected after 24 hours of transfection and stored at 4°C under 
Standard Operating Conditions for handling lentiviral-containing cultures. 5 ml of 
fresh growth media were added to the cells and incubated for an additional 24 
hours. Supernatant collected at 48 hours after transfection was harvested and 
mixed with the 24 virus-containing media. Next, the total volume of conditioned 
media was passed through a 0.45 µm filter and transferred into vials containing 
1 ml aliquots. Vials were stored at -80°C. 
 
2.11 Generation of stable knockdown cell lines   
For lentiviral transduction, 1 ml of virus-containing media was thawed in water 
bath or bead bath at 37°C and added to cells in T25 flask containing 4 ml of 
growth media with 10 µg/ml of polybrene (Alfa Aesar). After 24 hours of incubation 
at 37°C and 5% CO2, media with polybrene was replaced with fresh growth media  
and cells were incubated for an additional 24 hours at 37°C and 5% CO2. Next, 
growth media with puromycin was added to the cells to start selection. Cells were 
monitored daily and considered virus-free after two weeks of culture or after 2 
passages. Fresh media with puromycin was changed at least twice a week. Table 












Parental cell line Species ITM2A knockdown cells 
HEK293 Human HEK293 shITM2A-A 
HEK293 shITM2A-B 
HEK293 shITM2A-C 
HeLa Human HeLa shITM2A-A 
HeLa shITM2A-B 
HeLa shITM2A-C 
C2C12 Mouse C2C12 shItm2a-A 
C2C12 shItm2a-B 
C2C12 shItm2a-C 
Table 2.3 In-house generated cell lines with silenced expression of ITM2A 
 
 
2.12 Bafilomycin A1 treatment  
Bafilomycin A1 (BafA1) (Tocris) stock solutions at a concentration of 200 µM were 
prepared by dissolving BafA1 powder in dimethyl sulfoxide (DMSO). To inhibit 
autophagic flux, cells were treated with 100 nM of BafA1 for 4 hours before cell 
lysis. BafA1 was pipetted into an Eppendorf tube, containing 1 ml of growth media 
and mixed by pipetting up and down. Media containing BafA1 was added 
dropwise directly into the well. Control cells were treated with the same volume 
of DMSO.  
 
2.13 Preparation of cell lysates for Western blotting  
The procedure for lysing the cells was carried out on ice. Cells were washed with 
ice-cold 1x PBS. 150 µl of 1x Laemmli buffer (Sigma) were added to each well of 
a 6-well plate. Cell lysates were harvested using a cell scrapper and transferred 
to a pre-chilled Eppendorf tube and placed on ice. Lysates were sonicated on ice 
for 20 seconds at 15 amplitude, incubated in a heat block for 5 minutes at 95°C 
and stored at -80°C. Alternatively, when comparing samples with transfected 






PTCH1, after sonication the lysates were incubated for 30 minutes at 45°C in a 
heat block and stored at -80°C. 
 
2.14 Co-immunoprecipitation  
HEK293 were transiently transfected using LipofectamineTM 2000 as described 
earlier. Co-immunoprecipitation (Co-IP) assay was carried out in 10 cm culture 
dish, when two different test plasmids were transfected in the same reaction, the 
total DNA quantity was composed of 4µg of each plasmid. Controls expressing 
just one test plasmid (4µg) were brought up to a total of 8 µg total DNA with empty 
pcDNA3.1 vector. 24 hours after transfection, cells were placed on ice, washed 
with 2 ml of ice-cold 1x PBS and scrapped into 700µl of Co-IP lysis buffer (50 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.05% Sodium deoxycholate, 1 mM 
EDTA, 2.5 Mm MgCl2) supplemented immediately before use with 1x Expedeon 
Proteoloc protease inhibitor cocktail (AEBSF, aprotinin, bestatin, E-64, leupeptin 
and pepstatin A), 0.2 mM PMSF and 1mM DTT. Lysates were transferred to pre-
chilled Eppendorf tubes. Lysates were incubated with rotation at 4°C for 30 
minutes and then centrifuged at 13000 RPM for 15 minutes at 4°C to remove 
debris. Supernatant was transferred to a new 1.5 ml  Eppendorf tube and kept on 
ice, 200 µl of collected supernatant were set apart on ice as whole cell lysate 
(WCL). Supernatant was incubated with primary antibody (Table 2.4) at 4°C with 
rotation for 1.5 hours. Next, 30 µl of Dynabeads Protein G (Invitrogen) were 
added and incubated for 1 hour at 4°C with rotation. A magnetic rack was used 
to collect and then wash the beads three times with 1 ml of Co-IP lysis buffer. 
After removing the last wash, 18 µl of 2x Laemmli buffer (Sigma) were added to 
the beads and mixed. The previously saved WCLs were mixed with 40 µl of 6x 






Laemmli buffer. Both, beads and WCL, were incubated on heat block at 45°C for 
25 minutes and stored at -80°C for Western blotting.  
 




Mouse 4 ug Proteintech 66008-3-Ig 
GFP tag 
(Monoclonal) 
Mouse 4 ug Proteintech 66002-1-g 
Ha tag (Monoclonal) Mouse 4 ug Proteintech 66006-2-Ig 
MYC-tag 
(Polyclonal) 
Rabbit 4 ug Proteintech 16286-1-AP 
Table 2.4 Antibodies used for Co-IP assays 
Information of the antibodies used for Co-IP experiments. 
 
2.15 Western Blotting  
SDS-PAGE (Sodium Dodecyl Sulfate-PolyAcrylamide Gel Electrophoresis) 
technique was used to separate proteins based on their molecular weight. Cell 
lysates and Plus ProteinTM Dual Colour Standard Marker (Bio-Rad) were loaded 
in 8% or 13% hand-cast polyacrylamide gels (acrylamide:bisacrylamide 29:1) or 
in 4-20% Mini-PROTEAN® TGXTM precast protein gels (Bio-Rad, 4561093). 
Hand-cast gels were placed in 1x Running Buffer (25 mM Tris, 192 mM glycine, 
0.1% SDS, pH 8.3, Alfa Aesar) and separated at 85V for 30 minutes and then at 
120V for approximately 90 minutes. Precast gels were run without samples for 
10 minutes at 100V, then samples were loaded and run at 140V for approximately 
60 minutes. Proteins were transferred from the gel to a PVDF membrane (Bio-
Rad) by wet transfer using ice-cold 1x Transfer buffer (25 mM Tris, 192 mM 
glycine, pH 8.5, Alfa Aesar) + 20% Methanol (Fisher Scientific) at 50V for 2 hours. 
After transfer, membranes were blocked in 5% nonfat dried milk (PanReac 






AppliChem) diluted in Tris-buffered saline (TBS) with 0.1% Tween 20 (TBST) at 
room temperature for 1 hour. After blocking, membranes were washed for 5 
minutes in TBST and, unless otherwise specified, incubated overnight with 
primary antibody at 4°C at the specified concentration (Table 2.5) with gently 
rocking. After incubation with primary antibody, membranes were washed 3 times 
with TBST for 10 minutes per wash and incubated with appropriate secondary 
antibody (Table 2.6) in 5% milk in TBST for 1 hour at room temperature. Next, 
membranes were washed 3 times with TBST for 10 minutes. Detection of the 
proteins of interest was carried out by adding ClarityTM Western ECL Substrate 
(Bio-Rad) to the membranes and visualised in ChemiDoc Imaging System (Bio-
Rad) using Image Lab software (Bio-Rad). Western blot signals were analysed 
later using ImageJ software and normalised to loading control (β-actin or 
GAPDH). 
 












Rabbit 1:1000, 5% BSA CST 2546 
CDK4 (DCS156) 
(Monoclonal) 
Mouse 1:1000, 5% milk CST 2906 
CDK6 (DCS83) 
(Monoclonal) 
Mouse 1:2000, 5% milk CST 3136 
Cyclin D1 (DCS6) 
(Monoclonal) 
Mouse 1:1000, 5% milk CST 2926 
Cyclin D3 (DCS22) 
(Monoclonal) 
Mouse 1:2000, 5% milk CST 2936 
p21 Cip1/Waf1 
(12D1)(Monoclonal) 
Rabbit 1:1000, 5% BSA CST 2947 
DYKDDDDK Tag 
(D6W5B) 
Rabbit 1:1000, 5% BSA CST 14793 
DYKDDDDK tag 
(Monoclonal) 
Mouse 1:2000, 5% milk Proteintech 66008-3-Ig 








Mouse 1:1000, 5% milk CST 2955 
GFP tag 
(Monoclonal) 
Mouse 1:4000, 5% milk Proteintech 66002-1-g 
HA-Tag (C29F4) 
(Monoclonal) 
Rabbit 1:1000, 5% BSA CST 3724 








Mouse 1:4000, 5% milk Proteintech HRP-
60004 




Mouse 1:1000, 5% milk CST 2276 
MYC-tag 
(Polyclonal) 




Mouse 0.2µg/ml, 5% 
milk 
DSHB MF20 
LC3B (Polyclonal) Rabbit  1:1000, 5% BSA CST 2775 
SQSTM1/p62 
(Polyclonal) 
Rabbit  1:1000, 5% BSA CST 5114 
Table 2.5 Primary antibodies 
Information of the primary antibodies used for Western blotting. *ITM2A antibody 
was incubated for 1.5 hours at room temperature. Abbreviations: BSA=Bovine 
serum albumin (Sigma), DSHB=Developmental Studies Hybridoma Bank, 
CST=Cell signaling Technology.  
 
Primary antibody Dilution Company Catalogue 
number 
Goat anti-rabbit IgG (H + L)-HRP 
conjugate 
1:4000  Bio-Rad 1706515 
Goat anti-mouse IgG (H + L)-HRP 
conjugate 
1:4000  Bio-Rad 1706516 
Table 2.6 Secondary antibodies 
Information of secondary antibodies used for Western blotting.  
 
 






2.16 Densitometric analysis of gels  
Western blotting results were analysed by densitometry. Each band, at the 
expected molecular weight was quantified using ImageJ. The obtained values of 
the target protein, after subtracting the background, were normalised to the 
values of the loading control (β-actin or GAPDH). For the semi-quantitative 
measurement approach of the autophagic flux, the mean changes of the 
densitometric quantification of LC3B-II (normalised to control) of the samples 
treated with BafA1 over its level with vehicle (DMSO) were obtained. This 
approach accounts for the variability  in control samples.  
 
2.17 Gli-Luciferase reporter assay  
NIH3T3 cells and MEFs were used for this assay. Cells were seeded in a 10 cm 
culture dish and grown to a confluence of ~90%. Cells were washed with PBS, 
detached using 2 ml of trypsin and diluted in 8 ml of fresh growth media. Cells 
were then seeded in 24-well plates at a 1:5 dilution, 0.5 ml/well in growth media. 
24 hours after seeding, cells were transiently transfected. Different transfection 
reagents were used for each cell line: TransIT-2020® (Mirus) for NIH3T3 cells, 
and TransIT-X2® (Mirus) for MEFs. 
A master mix consisting of Opti-MEM® (50 µl/well), reporter construct p8xGBS-
Luc (135 ng/well) and reporter construct pRL-SV40 (15 ng/well) or pRL-TK (15 
ng/well) was prepared in an Eppendorf tube, vortexed briefly and aliquoted (1 
tube per well, 50 µl/well). Next, a total of 375 ng of plasmid DNA (containing a 
single plasmid or a combination of plasmids) was added directly into the 
Eppendorf tubes containing the aliquoted master mix, followed by the addition of 
1.5 µl/well of the transfection reagent, vortexed briefly and incubated for 30 






minutes at room temperature. Next, this mix was added drop-wise into the wells 
and cells were incubated for 24 hours. Transfected cells were washed with 0.5 
ml of 1x PBS and incubated with serum starvation media (DMEM, 0.5% FBS, 1% 
GlutaMAX) for an additional 48 hours. Cells were washed with 0.5 ml of 1x PBS 
and lysed with 100 µl of 1x passive lysis buffer (Promega) with vigorous shacking 
at room temperature for 15 minutes. Dual-luciferase reporter assay system 
(Promega) was used to measure the activity of Gli-dependent Firefly luciferase 
and normalisation control Renilla luciferase using a Promega Glomax 20/20 
luminometer. Values of the individual measurements were generated as relative 
luciferase units (RLUs) and as Firefly-luciferase/ Renilla-luciferase ratio.  
 
2.18 Bacterial transformation  
Escherichia coli (E. coli) DH5α competent cells were used for the transformation 
of previously validated or purchased plasmids. DH5α cells were thawed on ice 
and 100 µl were transferred into to a pre-chilled Eppendorf tube containing 1 µg 
of plasmid DNA, mixed gently by flicking the tube and incubated on ice for 10 
minutes. Next, cells were heat shocked for 30 seconds at 42°C in a water bath. 
1 ml of SOC media (Thermo Fisher Scientific) was added to the Eppendorf tube 
and cells were incubated at 37°C and 225 RPM for 1 hour.  
For transformation of cloning products, the protocol for transformation was as 
follows. TOP10 competent E.coli (Invitrogen) were thawed on ice for 10 minutes, 
100 ng of DNA were added directly into the tube containing 50 µl of competent 
cells, gently mixed by flicking the tube and incubated on ice for 30 minutes. Cells 
were heat shocked at 42°C for 30 seconds and incubated on ice for an additional 






5 minutes. 950 µl of SOC media were added to the cells and incubated for 1 hour 
at  37°C with shacking at 225 RPM. 
After incubation, different volumes (25-100µl) were spread into Luria-Bertani (LB) 
(Invitrogen) agar plates containing the specific antibiotic corresponding to the 
plasmid antibiotic resistance, usually ampicillin (100 µg/ml) or kanamycin (50 
µg/ml). Plates were incubated overnight at 37°C. Next day, single colonies were 
picked from the transformation plate and placed into a 10 ml round-bottom tube 
containing 3 ml of LB broth supplemented with the required antibiotic and 
incubated at 37°C with and 225 RPM. Colonies containing previously validated 
DNA plasmids (1 colony per plasmid), were incubated ~8 hours to continue with 
maxiprep protocol. When part of a cloning procedure, multiple colonies were 
incubated overnight for miniprep protocol followed by sequencing.  
 
2.19 DNA extraction by Miniprep and sequencing 
EZ-10 Spin Column Plasmid DNA Miniprep Kit Low Copy Plasmid (Bio Basic) 
was used to extract and purify plasmid DNA. Briefly, after overnight incubation, 
1.5 ml from the overnight bacterial suspension were transferred into a Eppendorf 
tube and centrifuged at 12,000 RPM for 2 minutes. Bacterial pellet was re-
suspended with 100 µl of Solution I, incubated at room temperature for 1 minute, 
mixed with 200 µl of Solution II and incubated at room temperature for 1 minute; 
350 µl of Solution III were added, mixed, incubated  for 1 minute at room 
temperature and centrifuged at 12,000 RPM for 5 minutes. Supernatant was 
placed on a EZ-10 column and centrifuged for 2 minutes at 10,000 RPM. Column 
containing DNA was washed twice with 750 µl of wash buffer at 10,000 RPM  for 
2 minutes. Plasmid DNA was eluted with 50 µl of elution buffer by centrifugation 






at 10,000 RPM for 2 minutes. DNA concentration and purity were measured using 
NanoDrop 8000 spectrophotometer (ThermoScientific). Samples containing the 
highest yield and purity were sent for Sanger sequencing to validate the plasmid. 
Samples were sent to Source Bioscience or GENEWIZ and stored at -20°. 
Validated plasmids were transformed for maxiprep.    
 
2.20 DNA extraction by Maxiprep 
After incubation, the 3 ml of starter culture were used to inoculate 250ml of LB 
broth with the specific antibiotic and incubated at 37°C and 225 RPM overnight. 
Plasmid Maxi Kit (QIAGEN) was used for extraction and purification of the DNA 
plasmid. Briefly, inoculated LB broth was centrifuged at 6000 x g for 15 minutes 
at 4°C. Supernatant was discarded, and bacterial pellet re-suspended in 10 ml of 
P1 Buffer containing RNAse, 10 ml of buffer P2 were added and mixed gently by 
inverting the tube, and quickly incubated at room temperature for 5 minutes. 10 
ml of pre-chilled buffer P3, were added to the mix and mixed gently by inverting 
the tube and incubated on ice for 20 minutes. Mix was then centrifuged at 4 °C 
for 30 minutes at 20,000 x g. Supernatant was poured into a fresh centrifuge tube 
and centrifuged at 4 °C for an additional 15 minutes at 20,000 x g to remove all 
genomic DNA. During centrifugation, the QIAGEN-tip 500 column was 
equilibrated with 10 ml of QBT buffer. After centrifugation, supernatant was 
poured into the pre-equilibrated column, followed by 30 ml of the QF wash buffer. 
Column was placed in an sterile centrifuge tube and 15 ml of QC elution buffer 
were added to elute the plasmid DNA, 10.5 ml of isopropanol were added and 
mixed to precipitate the plasmid DNA, mixed gently and centrifuged at 4°C at 
15,000 x g for 1 hour. Supernatant was quickly discarded after centrifugation and 






pellet was washed with 2 ml of 70% ethanol and let to air-dry for around 10 
minutes. Purified DNA was dissolved in 500 µl of TE buffer (Sigma) and 
transferred to clean Eppendorf tube. DNA concentration and purity of each 
plasmid was measured using NanoDrop 8000 spectrophotometer. Plasmids were 
aliquoted at 250 ng/µl and stored at -20°C. 
 
2.21 Cloning 
PCR-based cloning was used to generate constructs corresponding to different 
fragments of the CTD of PTCH1. First, forward and reverse primers were 
manually designed to: 1) amplify fragments of the CTD of PTCH1, 2) add and N-
terminal ATG codon and a C-terminal HA-tag followed by a stop codon and 3) 
add a HindIII and XbaI restriction sites to the ends of the inserts (Table 2.7). 
Plasmid PTCH1-eGFP (generously provided by Peter Zaphiropoulos, Karolinska 
Institute), containing the human full length sequence for PTCH1 isoform M (the 
longest variant) was used as a template. Inserts were amplified with Phusion 
polymerase (New England Biolabs), using the PCR cycle conditions described in 
Table 2.8. 






















Cycle step Temperature Time Cycles 
Initial denaturation 98°C 30 seconds 1 
Denaturation 98°C 10 seconds  
30  Annealing 54°C 25 seconds 
Extension 72°C 45 seconds 
Final extension  72°C 7 minutes 1 
4°C Hold Hold 
Table 2.8 PCR Cycling conditions for amplification of CTD inserts 
 
PCR products were run on an agarose gel for their identification based on the 
expected size and then purified using GenEluteTM gel extraction kit (Sigma) 
according to manufacturer’s protocol. Next  Zero BluntTM TOPO® PCR Cloning kit 
(Life technologies) was used to clone the PCR products (blunt-end) into the 
pCRII-Blunt-TOPO® vector (linearized and activated with topoisomerase I). The 
cloning reaction was set up as described in Table 2.9, mixed gently and 
incubated for 5 minutes at room temperature, followed by transformation into One 
Shot® E. coli competent cells following manufacturer’s protocol. 
 
Reagent Volume 
PCR product 3 µl 
Salt solution 1 µl 
Sterile water 1 µl 
pCRII-Blunt-TOPO® 1 µl 
Table 2.9 Setup for TOPO cloning reaction 
 
 
Single colonies from the TOPO cloning transformation were selected and grown 
overnight in selective media (kanamycin). Next, plasmid DNA was purified using 
miniprep as described earlier (section 2.19). Plasmid DNA from minipreps and 
pcDNA3.1 vector were subjected to double enzyme digestion with HindIII-HF 






(New England Biolabs) and XbaI (New England Biolabs) as specified by the 
manufacturer. Double digested products were separated on a 1.5%  agarose gel 
and purified, their concentration was measured using NanoDrop 8000 
spectrophotometer. T4 ligase (New England Biolabs) reaction was set up as 
recommended by manufacturer using an insert:vector ratio of 3:1 and with 
overnight incubation at 16°C. Ligation products were heat-inactivated and 
transformed into TOP10 competent cells, followed by Sanger sequencing of 
single colony minipreps to verify the sequence as described in section 2.19.  
 
2.22 RNA extraction  
RNA extraction from cultured cells was performed using the RNeasy® Mini Kit. 
Media was aspirated from each well and cells washed with 1x PBS, 350 µl of 
buffer RLT (containing freshly added 10 µl β-mercaptoethanol/ml) were added 
directly to each well and cell lysate was harvested using a cell scrapper. Cells 
were homogenised by vortexing for 1 minute, followed by addition of 350 µl 70% 
ethanol, mixed by pipetting, transferred to RNeasy Mini spin column and 
centrifuged at 8000 x g for 15 seconds. The column was then consequently 
washed with 700 µl of RW1 and centrifuged for 15 seconds, with 500 µl of RPE 
buffer and centrifuged for 15 seconds, and again with 500 µl RPE buffer and 
centrifuged for 2 minutes. After discarding the flow-through, the columns 
containing RNA were centrifuged for an additional minute and transferred to a 
fresh collection tube. 35 µl of RNAse-free water were added directly onto the 
column membrane and centrifuged for 1 minute. RNA concentration and RNA 
quality were measured using NanoDrop 8000 spectrophotometer and RNA 
samples were stored at -80°C.  






2.23 Synthesis of cDNA 
iScriptTM Select cDNA Synthesis Kit (Bio-Rad) was used to transcribe RNA into 
complementary DNA (cDNA). Briefly, the reaction was setup on ice using random 
primers and 1 µg RNA, as specified by manufacturer. Reactions were incubated 
in a thermocycler using the protocol described on Table 2.10. cDNA was stored 
at -20°C for future use. 
 
Step Temperature Time 
Priming 25°C 5 minutes 
Reverse transcription 42°C 30 minutes  
Heat-inactivation 85°C 5 minutes 
Hold 4°C ∞ 
Table 2.10 cDNA synthesis protocol 
 
 
2.24 Quantitative real-time PCR (qPCR) 
Quantitative PCR (qPCR) of the reverse transcribed cDNA was carried out using 
SsoFastTM EvaGreen® Supermix (Bio-Rad). Primers’ sequences are listed in 
Table 2.11. All primers were used at a concentration of 5 µM. The reaction was 
set up as specified by manufacturer in 96-well qPCR plate. Plate was centrifuged 
for 1 minute at 1000 RPM. Cycling conditions specified in Table 2.12, GAPDH 



















Reverse  GGTCTTCTCGAACCACATAAGTTTG 
Mouse Forward CGCACTGTCCGAGCTCAAAT 
Reverse  CATCTCCCAGATGAGCCATC 
Ptc1 
 
Mouse Forward ATGGTCCTGGCTCTGATGAC 
Reverse  TAGCCCTGTGGTTCTTGTCC 
GAPDH 
 
Human Forward TCCCATCACCATCTTCCA 
Reverse  CATCACGCCACAGTTTCC 
Mouse Forward AGTATGATGACATCAAGAAGG 
Reverse  ATGGTATTCAAGAGAGTAGGG 
Table 2.11 Details of qPCR primers  
 
Cycling step Temperature Time Cycles 
Enzyme activation 95°C 30 seconds 1 
Denaturation 95°C 5 seconds 40 
Annealing/extension *55-60°C 5 seconds 
Melting curve  65-95°C 
(increment 0.5°C) 
5 seconds/step 1 
Table 2.12 Cyclin conditions for qPCR 
*Annealing temperatures: ITM2A=57°C, Ptc1=59°C. 
 
Fold changes of target genes were calculated with the 2^ΔΔCt method, where 
ΔCt is the difference of the Ct value between the target gene minus the Ct value 
of the control gene (GAPDH), and the second Δ is the difference between the 
treatment (shRNA or overexpression) and its control (scramble shRNA or empty 
vector). 
 
2.25 Preparation of immunoprecipitates for mass spectrometry  
To prepare the samples for proteomic analysis, HEK293 were seeded in 10 cm 
culture dishes at a concentration of 3 x105 and transiently transfected after 24 






hours with either, HA-ITM2A or pcDNA3.1, as stated previously in this chapter, 
using 8 µg of DNA and 20 µl of LipofectamineTM 2000. 24 hours after 
transfection, cells were washed with 2 ml of ice-cold 1x PBS and collected with 
700 µl of the Co-IP lysis buffer described in section 2.14. Lysates were transferred 
to pre-chilled Eppendorf tubes and pre-cleared with rotation at 4°C for 30 minutes 
and then centrifuged at 13000 RPM for 15 minutes at 4°C. Supernatant was 
transferred to a new 1.5 ml  microcentrifuge tube and incubated with 2 µl of 
normal IgG and 30 µl of Dynabeads Protein G for 30 minutes at 4°C with rotation. 
Supernatant was separated from Dynabeads using a magnetic rack and later 
incubated with and anti-HA primary antibody (Proteintech) at 4°C with rotation for 
1.5 hours. Next, 30 µl of Dynabeads Protein G were added and incubated for 1 
hour at 4°C with rotation. A magnetic rack was used to collect and then wash the 
beads three times with 1 ml of Co-IP lysis buffer. 18 µl of 1x Laemmli buffer 
(Sigma) were added to the beads, mixed and incubated on heat block at 45°C for 
25 minutes and stored at -80°C before submission for mass spectrometry 
analysis . Samples were submitted in solution form to the mass spectrometry 
facility of the University of Leeds for the identification of immunoprecipitation-
interacting protein partners and for the detection of protein post-translational 
modifications. Protein digestion of samples was carried out with trypsin. Data was 
processed by the facility using the software Peaks.  
 
2.26 Statistical analysis  
GraphPad Prism software version 9 was used for the statistical analysis and for 
the generation of graphs. Unless otherwise specified, three biological replicates 
were performed. Error bars are shown as standard error of the mean (SEM, n=3). 






One-tailed and two-tailed paired Student’s t-test were used to analyse the 
significant difference between two groups. One-way ANOVA analysis was 
selected to analyse at least three different groups when the samples showed 
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Chapter 3                                                                           
PTCH1 reduces autophagic flux by interactions of its C-
terminal domain with ATG101 
3.1 Introduction 
Different studies have shown that the Hh signalling pathway plays an important 
role during embryonic development, in the maintenance of homeostasis in adult 
structures and that dysregulation of the pathway is linked to different cancer types 
and many other human pathologies (Goodrich et al., 1996; Carballo et al. 2018). 
PTCH1 is the principal and most studied receptor of the Hh pathway. PTCH1 is 
expressed in different tissues and its deficiency is embryonic lethal (Goodrich et 
al., 1997). Secondly, mutations that render PTCH1 non-functional are related to 
the development of medulloblastoma and basal cell carcinoma in humans 
(Gailani et al., 1996; Goodrich et al., 1997; Kogerman  et al., 2002; Banerjee et 
al., 2019). PTCH1 is widely known as a tumour suppressor, mainly by the 
regulatory action that it has on the Hh canonical pathway through inhibition of the 
oncogene SMO. Repression of SMO results in blocking of the transcriptional 
activity of the Gli family of proteins and, therefore,  prevents activation of Hh target 
genes (Ingham and McMahon, 2001). While the 12-transmembrane and the 
extracellular domains of PTCH1 are necessary for the inhibition of SMO, the CTD 
does not play a role in SMO repression. Nevertheless, it is necessary for PTCH1 
turnover (Lu et al., 2006; Kawamura et al., 2008; Fleet et al., 2016).  
PTCH1 interacts with an array of proteins, therefore it is possible that some of the 
interactions could be contributing to its tumour suppressor role independently of 
SMO activation and, thus, they are not related to its function in canonical Hh 






signalling. Previous studies in our lab have shown that the CTD of PTCH1 is 
involved in the regulation of apoptosis and turnover by interaction with the 
DRAL/procaspase-9 complex and the ubiquitin E3 ligase ITCH  (Thibert et al., 
2003; Chen et al., 2014). In order to identify additional interactors of the CTD, a 
previous postdoc in the Riobo Del-Galdo lab (Dr. Lucy Chen) performed a yeast-
two-hybrid screening using the CTD as bait. Identification of an autophagy related 
protein was followed by validation and functional studies, which are briefly 
described below to provide context to my direct contribution, which resulted in my 
first publication (Chen et al., 2018). 
 
3.2 Results 
3.2.1 Autophagic flux is regulated by the interaction between 
ATG101 and the C-terminal domain of PTCH1.  
Using the yeast two-hybrid screening system, the Riobo-Del Galdo lab used the 
C-terminal domain (CTD) of PTCH1 as the bait to identify new interacting 
proteins. One of the proteins identified using this technique was ATG101. 
Validation of the physical interaction of ATG101 with PTCH1 was carried out in 
HEK293 cells. Co-immunoprecipitation experiments with different PTCH1 
constructs showed that the CTD is both necessary and sufficient for interaction 
with ATG101. Confocal microscopy studies showed that PTCH1 co-localises with 
ATG101 to a high degree, further confirming the interaction of these proteins 
(Chen et al., 2018). As previously mentioned, ATG101 is part of the mammalian 
autophagy initiation complex. This complex is formed by FIP200, ULK1/2 and 
ATG13 (Hara et al., 2008; Hosokawa et al., 2009a; Hosokawa et al., 2009b). The 
obtained results showed that PTCH1 is capable of interacting with the entire ULK 






complex, and that this interaction is mediated by the direct interaction between 
PTCH1 and ATG101 (Figure 3.1). Considering that PTCH1 interacts with the 
autophagy initiation complex, different assays were carried out to understand the 
functional consequences of this interaction on autophagy regulation. Analysis of 
changes in the level of the autophagy markers LC3B-II and p62 in HEK293 and 
HeLa cells in the presence and absence of lysosomal inhibitors such as BafA1 
and chloroquine, showed that expression of PTCH1 blocks the autophagic flux 
(Chen et al., 2018). The tandem fusion protein eGFP-RFP-LC3B was used as a 
complementary approach to validate the effect of PTCH1 on autophagic flux. 
eGFP-RFP-LC3B displays green and red fluorescence in autophagosomes, but 
only red fluorescence after formation of autolysosomes due to the low pH, 
allowing the quantification of “successful” autophagy completion. Overexpression 
of PTCH1 reduced the formation of autolysosomes, confirming the blocking effect 











Figure 3.1 Simplified schematic representation of the interaction between 
the C-terminal domain of PTCH1 and ATG101 
The ULK complex is formed by ULK1/2, ATG13, ATG101 and FIP200. PTCH1 
interacts with the entire ULK complex through ATG101. The interaction between 
PTCH1 and ATG101 is mediated by the CTD of PTCH1. Created with 
BioRender.com. 
 
Experiments using transient silencing of ATG101 showed that the autophagic 
blockade phenotype observed after expression of PTCH1 is driven mostly by its 
interaction with ATG101.  Considering that the CTD of PTCH1 is not required for 
the canonical Hh signalling pathway, Smo-/- MEFs were used to confirm if the 
autophagic flux blockade was following a non-canonical Hh signalling pathway. 
Smo-/- MEFs are unable to activate the Hh canonical pathway. Smo-/- MEFs were 
transfected with construct SmoM2, a constitutively active (even in the presence 
of PTCH1) Smo mutant or empty vector. Overexpression of PTCH1 in the cells 
deficient of Smo or those expressing the active SmoM2 mutation caused the 
same inhibition of autophagy like the one observed in HEK293 and HeLa cells 
while activation of canonical pathway was not affected (Chen et al., 2018). To 






further rule out an involvement of the canonical Hh pathway in the autophagic 
block function by PTCH1, HEK293 cells were transfected with PTCH1 and treated 
in the absence or presence of SMO inhibitor KAAD-cyclopamine. The analysis of 
results showed that even in the presence of the KAAD-cyclopamine, PTCH1 
expression led to a block in autophagy. These results suggest that the autophagic 
flux phenotype generated by expression of PTCH1 does not require SMO 
repression by PTCH1 and, thus, the autophagic flux blockade is independent of 
SMO activity. Therefore, the autophagic flux blockade exerted by PTCH1 is 
categorised in the Hh non-canonical signalling pathway. Considering that Shh 
regulates the proapoptotic activity of PTCH1, which is also mediated by the CTD 
of PTCH1, HEK293 cells were transfected with PTCH1 and Shh to understand if 
the Hh ligands could prevent the effect of PTCH1 on autophagy. Analysis of 
autophagy markers LC3B-II and p62 showed that co-expression of PTCH1 and 
Shh reverted the autophagic block phenotype observed when PTCH1 is 
expressed alone. These results indicate that the Hh proteins can inhibit the 
blocking effect of PTCH1 on autophagy (Chen et al., 2018).  
 
3.2.2 Endogenous Patched1 reduces autophagic flux in mouse 
embryonic fibroblasts 
At the beginning of my PhD, I investigated the effect of endogenous Ptc1 (mouse 
homolog of PTCH1) on autophagy using mouse embryonic fibroblasts (MEFs) 
from Ptc1-/- mice or Ptc1+/- littermates. My results showed that the accumulation 
of LC3B-II and p62 in response to the inhibitory effect of BafA1 was higher in 
Ptc1-/- than in Ptc1+/- (Figure 3.2). This result is in agreement with the negative 
regulation of autophagy by PTCH1 and suggests that loss of endogenous 






Patched1 increases the basal autophagic flux in a measurable manner (Chen et 
al., 2018).  
Taken together, these results show that a novel function  of PTCH1 expression 
is to restrain autophagic flux, a new type of non-canonical Hh signalling. The 
decrease in the autophagy rate could be caused by the impairment of the fusion 
between autophagosome and lysosomes or by inhibiting the acidification of the 
autolysosomes, since the defect is observed at the last step of autophagy (Chen 
et al., 2018). 
 
 
Figure 3.2 Expression of endogenous Patched1 restrains autophagic flux 
A. Expression levels of p62 and LC3B-II in Ptc1-/- and Ptc1+/- MEFs after 4 h in 
EBSS with or without addition of 100 nM Bafilomycin A1 (BafA1). Representative 
experiment of n=3. B. Densitometric quantification of autophagy markers LC3B-






II and p62 western blot signals normalized to β-Actin in comparison to pcDNA3.1 
(n=3; * P < 0.05). Adapted from (Chen et al., 2018).   
 
 
3.3 Discussion  
Growing evidence suggest that PTCH1 acts as a tumour suppressor, 
independently of and in addition to its role as SMO repressor. The CTD of 
PTCH1, is not involved in its role of SMO repressor. However, is important for 
PTCH1 turnover and for its pro-apoptotic function (Mille et al, 2009).  
We showed that the CTD of PTCH1 interacts with ATG101 causing an inhibition 
of the autophagic flux through a non-canonical type I Hh signalling. Considering 
that the effect of the interaction of PTCH1 with ATG101 occurs downstream the 
formation of the ULK1 complex, and that it leads to an accumulation of 
autophagosomes that cannot be degraded, further studies are necessary to 
understand the mechanistic basis of the autophagic flux blockade induced by 
PTCH1 (Chen et al., 2018). 
This novel function of PTCH1 is potentially relevant in the study of specific cancer 
types, such as colorectal, gastric and endometrial cancers. Mutations in the CTD 
of PTCH1 could give cancers cells a survival advantage by evasion of the 
autophagic flux inhibition mechanism. Further studies are required to fully 
elucidate the functional consequences of the interaction between PTCH1 and 
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Chapter 4                                                                        
Changes in autophagic flux by cancer-associated PTCH1 
mutations in its C-terminal domain 
4.1 Introduction 
Previous studies in our lab have shown that the CTD of PTCH1 is involved in the 
regulation of apoptosis and autophagy by interaction with the DRAL/procaspase-
9 complex and ATG101 (Chen et al., 2014; Chen et al, 2018). Therefore, it is only 
logical to hypothesise that mutations in the CTD that could jeopardize the binding 
of those interacting proteins might have important functional consequences on 
the processes they regulate.  
Autophagy is a homeostatic catabolic process that occurs as a response to an 
array of biological functions that include, amongst others, adaptation to nutrient 
depleted conditions, oxidative stress, cellular remodelling during development 
and differentiation (Yorimitsu and Klionsky, 2005). Dysregulation of autophagy 
has been linked to different human diseases that include degenerative disorders, 
inflammatory conditions and cancer. The study of autophagy as well as the 
proteins involved in the process is becoming more important as it can provide 
different targets to treat disease (Levine and Kroemer, 2008). 
The role of autophagy in cancer is less clear, with controversial evidence 
supporting a context-dependent positive or negative influence. Activation of 
autophagy has been frequently observed in growing tumours. Tumours need 
nutrients to sustain their growth and these nutrients are supplied by autophagy. 
In this scenario, blocking of autophagy could be used to treat cancer. In addition, 
a protective role of autophagy by degradation of accumulated damaged 
organelles and from the potential generation of toxic substrates, such as reactive 






oxygen species, was also proposed (White, 2012; Galluzzi et al., 2015). However, 
autophagy was also shown to contribute to the elimination of early cancer cells 
before a tumour mass is established, opposing tumour initiation (Bhutia et al., 
2013). Considering that our results suggest that tumour suppressor activity of 
PTCH1 could be partially dependent on its inhibitory function on autophagy 
mediated by the CTD, we searched for PTCH1 CTD mutations in the Cancer 
Genome Atlas (TCGA) database (unpublished observations). Remarkably, we 
found three somatic mutations in the CTD of PTCH1 that are overrepresented in 
~5% of colorectal cancers, ~2.7% gastric cancer and ~7.5% of endometrial 
cancers. Findings in the colorectal cancer cases were further validated by two 
independent cohorts: the UK 100,000 Genome Project and the Norwegian Series 
I, where the incidence of the three most common CTD mutations in colorectal 
cancer cases was also found to be 4.1% and 6% respectively (unpublished 
observations; Sveen et al., 2017). Two of these mutations are frameshift-causing 
indels that cause sequence changes after S1203 and R1308 and result in 
premature truncation of PTCH1. The third one is a substitution in the PPxY motif: 
Y1316T. Both mutations that cause the truncation have lost the ubiquitylation site 
(K1426), and the caspase cleavage (D1405), which is required for the pro-
apoptotic activity of PTCH1, and all three lack the PPxY motif essential for 
interaction with ITCH, an E3 ubiquitin ligase that mediates PTCH1 turnover (Lu 











4.2 Aims  
Given that the interaction of PTCH1 with ATG101 occurs through the CTD and 
that this region is a hot spot for somatic mutations that have been linked to 
specific types of cancer, it was decided to investigate what could be the functional 
consequences of the cancer mutations on the regulation of autophagy and their 
binding ability to ATG101.  
The specific aims of this part of my doctoral investigation were:  
 Generation of constructs encoding the three identified PTCH1 CTD cancer 
mutants. 
 Analysis of the interaction of ATG101 with the PTCH1 cancer-associated 
mutants.  
 Investigation of the functional capacity of the CTD cancer mutants to 



















4.3 Results  
4.3.1 Generation of cancer mutations in the CTD of PTCH1. 
There are three specific mutations and truncations in the CTD of PTCH1 that, 
according to the Cancer Genome Atlas TCGA database, are overrepresented in 
colorectal cancer, stomach cancer and endometrial cancer (Figure 4.1).  
 
 
Figure 4.1 Simplified schematic representation of significant structural 
elements and somatic mutations found in the CTD of PTCH1 
Yellow boxes represent the approximate position of Proline-rich motifs. The green 
line represents the caspase cleavage site. The grey line represents ubiquitylation 
site. The black lines represent somatic mutations found in the TCGA database. 
 
I supervised MNatSci student G. Jenkins to perform site directed mutagenesis to 
engineer the three mutants from a plasmid encoding  wild type PTCH1 with N-
terminal Myc tag: Myc-PTCH1(1-1308), Myc-PTCH1(1-1203) and Myc-
PTCH1(Y1316T) (Figure 4.2A). The generation of these mutants was confirmed 
by Sanger sequencing (data not shown) and subsequently analysed by Western 
blotting.  
Additionally, subcloning of the CTD via PCR amplification and addition to start 
and stop codons and novel restriction sites was performed to generate two 
constructs encoding the isolated CTD of PTCH1 with a C-terminal HA-tag: full 






length CTD(1179-1447)-HA and the shorter cancer mutant CTD(1179-1308)-HA  
(Figure 4.2B). Each construct was confirmed by Sanger sequencing. However, 
expression of the CTD(1179-1308)-HA mutant at the protein level could not be 
consistently detected by western blotting. It is possible that mutant CTD(1179-
1308)-HA was unstable and degraded or that the HA-tag epitope was somehow 
occluded from the antibody. Another possibility is that the expression levels are 
below the detection limit by Western blotting. 
Two additional CTD constructs of interest with C-terminal HA-tags were designed 
and synthesised using a commercial source (Agentide): cancer CTD mutant 
CTD(1179-1203)-HA and CTD fragment CTD(1308-1447)-HA (Figure 4.2B). 
Expression controls of these CTD fragments showed that only the CTD(1308-
1447)-HA construct was readily expressed by Western blotting, while the cancer-
associated mutant CTD(1179-1203)-HA could not be detected (data not shown). 
Table 4.1 summarises the principal characteristics of the generated constructs. 
Western blots for the validation of the expression of the generated PTCH1 
constructs are shown in Figure 4.3A&B.  
 







Figure 4.2 Simplified schematic representation of constructs 
corresponding to the cancer-associated mutations in the CTD of PTCH1 
found in the TCGA database 
Yellow boxes represents the approximate position of Proline-rich region. A. Full 
length constructs of PTCH1. From top to bottom: Myc-PTCH1(1-1447), Myc-
PTCH1(1-1308), Myc-PTCH1(1-1203) and Myc-PTCH1(Y1316T). B. CTD 
constructs of PTCH1. From top to bottom: CTD(1179-1447)-HA, CTD(1179-
1308)-HA, CTD(1179-1203)-HA and CTD(1308-1447)-HA. 
 
Table 4.1 Principal characteristics of generated PTCH1 constructs 
 





CTD(1179-1447)-HA C-terminal  30 kDa Yes 
CTD(1179-1308)-HA C-terminal  15 kDa No 
CTD(1179-1203)-HA C-terminal  4 kDa No 
CTD(1308-1447)-HA C-terminal  16 kDa Yes 
Myc-PTCH1(1-1203) N-terminal  135 kDa Yes 
Myc-PTCH1(1-1308) N-terminal  146 kDa Yes 
Myc-PTCH1(Y1316T) N-terminal  161 kDa Yes 







Figure 4.3 Detection of protein expression of generated PTCH1 mutants 
by Western blotting 
Detection of protein expression of generated PTCH1 mutants by Western 
blotting. A. Expression of Myc-PTCH1, Myc-PTCH1(1-1308), Myc-PTCH1(1-
1203) or Myc-PTCH1(Y1316T) in HEK293 cells, pcDNA 3.1 was used as control. 
B Expression of CTD(1179-1447)-HA, CTD(1179-1308)-HA or CTD(1308-1447)-
HA in HEK293 cells, pcDNA 3.1 was used as control.  
 
 
4.3.2 Loss of the CTD after R1308 abolishes interaction with ATG101 
To investigate the effect of the three CTD cancer mutations on their interaction 
with ATG101, HEK293 cells were co-transfected with full length Myc-PTCH1(1-
1447), Myc-PTCH1(1-1203), Myc-PTCH1(1-1308), Myc-PTCH1(Y1316T) or 
empty vector along with ATG101-FLAG. Co-immunoprecipitation of Myc-PTCH1 
showed that the interaction with ATG101 was only maintained with the Myc-
PTCH1(Y1316T) mutant (Figure 4.4A). Our previous study suggests that 
membrane localization of PTCH1 is not a pre-requisite for its interaction with 
ATG101 (Chen et al., 2018), therefore HEK293 cells were co-transfected with the 
soluble CTD constructs: full length CTD(1179-1447)-HA, N-terminal half 
CTD(1179-1308)-HA and C-terminal half CTD(1308-1447)-HA or empty vector 






along with ATG101-FLAG. Co-immunoprecipitation of CTD-HA fragments 
showed that the interaction with ATG101 was detectable in two of the CTD 
constructs: full length CTD(1179-1447)-HA and C-terminal half CTD(1308-1447)-
HA.  
However, it is important to highlight that there was no detectable protein 
expression of the fragment CTD(1179-1308)-HA (Figure 4.4B). Altogether, co-
immunoprecipitation studies using full length PTCH1 or the isolated CTD confirm 
that the 1308-1447 region mediates its interaction with ATG101 and that the two 


















Figure 4.4 The 1308-1447 region of the CTD of PTCH1, absent in two of the 
cancer-associated mutants, is necessary for interaction with ATG101 
A. HEK293 cells were transfected with ATG101-FLAG and full length Myc-
PTCH1, Myc-PTCH1(1-1308), Myc-PTCH1(1-1203) or Myc-PTCH1(Y1316T), 
pcDNA3.1 was used as control. 24 hours after transfection, cells were lysed and 
immunoprecipitated with Myc tag antibody, followed by analysis of ATG101-
FLAG in the IP and whole cell lysate (input).  B. HEK293 cells were transfected 
with ATG101-FLAG and CTD(1179-1447)-HA, CTD(1179-1308)-HA or 
CTD(1308-1447)-HA, pcDNA3.1 was used as control. 24 hours after transfection, 
cells were lysed and immunoprecipitated with anti-HA antibody, followed by 
analysis of ATG101-FLAG in the IP and whole cell lysate (input). 






4.3.3 Cancer mutations on the CTD of PTCH1 that disrupt the 
interaction with ATG101 affect the autophagy flux blockade 
induced by PTCH1  
As previously described, the methodologies used for the study of autophagy can 
be categorised into: qualitative (identification of autophagy-related structures and 
their fate) and semi-quantitative (measurement of the levels of autophagy 
proteins and cargoes that are selectively degraded during autophagy). 
Nonetheless, the study of autophagy remains complex, and most of the methods 
for the analysis of autophagic flux rely on measuring the changes in autophagic 
cargo degradation over time, a process known as “autophagic flux” (Yoshii and 
Mizushima, 2017). The most common method used to study autophagic flux 
involve the measurement of two forms of LC3B (homolog of the yeast Atg8 
protein). As previously mentioned, the LC3B precursor is first cleaved by ATG4 
generating LC3B-I. During autophagy LC3B-I is conjugated to PE to form LC3B-
II, which can be found embedded in the isolation membrane and in both, inner 
and outer membranes of the autophagosomes. As a result, LC3B-II is widely used 
as a marker for the identification of autophagy-related structures such as 
autophagosomes (Barth et al., 2010; Mizushima et al., 2010).  p62/SQSMT1 is a 
second autophagy marker protein. p62 interacts with ubiquitinated cargo and with 
LC3B-II to bring cargo into the autophagosome, with both p62 and its cargo being 
degraded through the autophagy process. Therefore, an increase in p62 protein 
levels in western blotting reflects a blocking in autophagy, as the protein cannot 
be degraded and is accumulated (Yoshii and Mizushima, 2017). 
We used the changes in those autophagy markers to investigate if the loss of the 
interaction of PTCH1 with ATG101 in the cancer-associated truncation mutants 






affects the regulatory function of PTCH1 on the autophagic flux. In addition, it was 
decided to investigate whether the mutation Y1316T, which maintains the 
interaction with ATG101, had any impact on the autophagy phenotype. 
Consequently, to understand the effect of the CTD cancer mutations on the 
autophagic flux inhibition exerted by PTCH1, HEK293 cells were transfected with 
Myc-PTCH1(1-14473), Myc-PTCH1(1-1203), Myc-PTCH1(1-1308), Myc-
PTCH1(Y1316T) or empty vector, and after 24 hours of transfection, the cells 
were treated with BafA1 or vehicle to investigate autophagy flux. Analysis of 
LC3B-II and p62 levels (Figure 4.5) showed that the Myc-PTCH1(1-1203) mutant 
does not inhibit autophagic flux, which was expected as this mutant losses its 
interaction with ATG101. Treatment with BafA1 on cells expressing the mutant 
Myc-PTCH1(Y1316T), which maintains the interaction with ATG101, showed 
similar results to wild type Myc-PTCH1(1-1447), suggesting a normal function. 
However, the Myc-PTCH1(1-1308) mutant, which like Myc-PTCH1(1-1203) is 
also unable to interact with ATG101, showed an intermediate autophagy flux 
phenotype between PTCH1 (1-1203) and wild type PTCH1. 
Taken together, these results show that the interaction of ATG101 with the CTD 
of PTCH1 occurs mainly in the region of the CTD that encompasses amino acids 
1308 to 1447, with additional requirements in the 1203-1308 region. These 
results also indicate that the mutation in the CTD that causes the amino acid 
substitution Y1316T does not disrupt the interaction with ATG101 and conserves 
the autophagy phenotype exerted by wild type PTCH1.  
 







Figure 4.5 Truncation of the CTD of PTCH1 at S1203 or R1308 attenuates 
autophagic flux blockade by wild type PTCH1 
Expression levels of p62 and LC3B-II in HEK293 cells transfected with pcDNA3.1, 
Myc-PTCH1(1-1447), Myc-PTCH1(Y1316T), Myc-PTCH1(1-1308) and Myc-
PTCH1(1-1203),  and cultured 24 hours in complete growth medium with or 
without the addition of  100 nM Bafilomycin (BafA1) during the last 4 h. 


















4.4 Discussion  
These results show that the interaction of ATG101 with PTCH1 occurs mainly in 
the CTD region comprising amino acid 1308 to 1447. However, additional weaker 
interactions of ATG101 with another region of the CTD of PTCH1 that 
encompasses amino acids 1179 and 1308 cannot be ruled out given the lack of 
detection of the protein expression by western blotting of the constructs 
corresponding to this fragment.  
With the help of MBiol student Michael Parkes, an analysis of the predicted 
secondary structure of the CTD fragments with the epitope tags was carried out. 
Five different proline regions were found on the CTD based on the following 
criteria: they contain at least one of the following, a proline motif, arginine 
residues or lysine residues. The construct CTD(1179-1308)-HA, contains 3 
proline rich regions in total, the first one characterised for a PxPxxxP motif and 
an arginine residue. The second one formed of a PxxP motif and arginine residue, 
and the third one formed by 3 arginines. The C-terminal HA tag of the CTD(1179-
1308)-HA generates an extra proline motif. Proline-rich motifs can form a 
polyproline II helix (PPII) (Zarrinpar et al., 2003). Therefore, the presence of the 
HA tag in the  CTD(1179-1308)-HA construct could result in a new PPII structure. 
This PPII structure is important as it could hide the HA epitope (Lopes et al., 
2014), and therefore obstruct the detection of the anti-HA antibody in western 
blotting experiments of the construct CTD(1179-1308)-HA. 
Furthermore, it would be interesting to understand if mutations in the caspase 
cleavage or in the ubiquitylation site, that are contained within the amino acids 
1308 and 1447 would disrupt the interaction with ATG101 and/or if they could 
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Chapter 5                                                                      
Interaction of the CTD of PTCH1 with ITM2A: characteristics 
and effect on autophagy in HEK293 and HeLa cells 
 
5.1 Introduction  
Recent findings in our lab show that the intracellular CTD of PTCH1 regulates 
autophagic flux by interacting with ATG101, a protein with a major role in the 
initiation of autophagy. Paradoxically, the phenotypic consequences of the 
interaction is observed at the end of the autophagic process, where PTCH1 
induces an autophagic flux blockade (Chen et al., 2018). Considering this, it is 
possible that PTCH1 is interacting with additional proteins to block autophagy 
completion. Incidentally, another research team published that ITM2A, a type II 
single pass membrane protein, blocks the autophagic flux at the same step as 
PTCH1 through an inhibitory interaction with V-ATPase that results in the 
accumulation of autophagosomes that cannot be degraded (Namkoong et al., 
2015). Although the function of ITM2A is not completely elucidated, it has been 
linked to differentiation of skeletal muscle, cartilage tissue and in T cell 
development. Nevertheless, its effects are cell type specific (Kirchner and Bevan, 
1999; Van den Plas and Merregaert, 2004a). Besides its role in autophagy and 
differentiation, ITM2A has been shown to be involved in breast and ovarian 
cancer, although with different consequences on autophagy (Nguyen et al., 2016; 
Zhou et al., 2019). 
It was decided to explore in detail the role of ITM2A since it was also identified in 
the yeast two-hybrid screen of PTCH1 CTD interactors, suggesting a potential 
functional interaction.  
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5.2 Aims  
Since ITM2A inhibits autophagy at the same step as PTCH1, and potentially 
interacts with it in mammalian cells, it was first hypothesised that ITM2A could be 
a mediator of the autophagic flux blockage by PTCH1. Therefore, the specific 
aims for this chapter are:  
 Validation of the interaction between PTCH1 and ITM2A in mammalian 
cells.  
 Investigation of the role of ITM2A expression on the negative regulation of 
autophagy by PTCH1. 
 Identification of the region of PTCH1 that is involved in the interaction with 
ITM2A. 
 Generation of stable cell lines with ITM2A knockdown to establish if the 
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5.3 Results  
5.3.1 PTCH1 physically interacts with ITM2A 
Former members of the Hedgehog lab previously identified novel proteins that 
could interact with the CTD of PTCH1. This was achieved by a  yeast-two-hybrid 
screening in which the GAL4 DNA-binding domain fused to the CTD of PTCH1 
was used as the bait to screen the mouse embryo E17cDNA library. The library 
was fused to the GAL4-activator domain (Chen et al., 2018). The most frequently 
recovered clone from the yeast-two-hybrid screening encoded for the mouse 
ITM2A protein, with 21 hits out of the 63 validated interactors (33%) (unpublished 
data). The involvement of ITM2A in autophagy had been recently published 
(Namkoong et al., 2015), therefore it was decided to validate ITM2A as an 
interacting protein of PTCH1 in mammalian cells. 
HEK293 cells were co-transfected with HA-tagged full length PTCH1, the isolated 
CTD (CTD(1179-1447)-HA), the N-terminal half of the CTD (CTD(1179-1308)-
HA) or empty vector along with Myc-ITM2A. Co-immunoprecipitation results 
confirmed the interaction of full length PTCH1 with ITM2A in mammalian cells 
(Figure 5.1A&B). Interestingly, and despite the fact that the yeast-two-hybrid 
screening was carried out with the CTD as bait, the results showed no interaction 
between ITM2A and the full length CTD of PTCH1 in soluble form. 
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Figure 5.1 PTCH1 physically interacts with ITM2A 
HEK293 cells were transfected with Myc-ITM2A and: PTCH1-HA or CTD(1179-
1447)-HA or CTD(1179-1308)-HA, pcDNA 3.1 was used as control. 24 hours after 
transfection, cells were lysed and immunoprecipitated with A. Anti-HA antibody, 
followed by analysis of Myc-ITM2A in the IP and whole cell lysate (input), and  B. 
Anti-Myc antibody, followed by analysis of PTCH1-HA  or CTD (1179-1447)-HA 
or CTD (1179-1308)-HA in the IP and the whole cell lysate (input).  
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Therefore, the next step was to understand if membrane localisation of PTCH1 
is a pre-requisite for its interaction with ITM2A. To answer this, the construct myr-
eGFP-CTD that localises the CTD of PTCH1 to the membrane through a 
myristoylation signal, was used. HEK293 cells were co-transfected with full length 
PTCH-eGFP, myr-eGFP-CTD or empty vector along with Myc-ITM2A. Co-
immunoprecipitation analysis showed that ITM2A interacts with the membrane-
bound CTD (Figure 5.2A), suggesting that membrane localization of PTCH1 is 
necessary for the interaction.  
To determine if ITM2A interacts with additional intracellular regions of PTCH1, 
we selected PTCH1 mutants with deletions in the cytoplasmic regions to 
understand if the removal of the intracellular regions of PTCH1 completely 
abolished the interaction with ITM2A.  
First we selected the mutant PTCH1∆ML-eGFP, with a deletion of the middle 
cytoplasmic loop (located between TM6 and TM7). In this mutant, all the 
cytoplasmic middle loop is removed except the first 9 amino acids and the last 18 
amino acids of the middle loop. We also selected the double deletion mutant: 
PTCH1∆ML-∆CTD-eGFP that, in addition to the previously described deletion of 
the middle loop, also lacks all the CTD except the first 11 amino acids of this 
region. The selected mutants were generated by PhD student Alex Timmis. 
HEK293 cells were co-transfected with eGFP-PTCH1, eGFP-PTCH1-∆ML, 
eGFP-PTCH1-∆ML-∆CTD, or empty vector along with Myc-ITM2A. Surprisingly, 
co-immunoprecipitation results show that ITM2A interacts with both PTCH1 
deletion mutants (Figure 5.2B), suggesting that ITM2A interaction with PTCH1 
is not constrained to the intracellular regions of PTCH1. In addition, ITM2A could 
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Figure 5.2 ITM2A physically interacts with multiple regions of PTCH1 
A. HEK293 cells were transfected with Myc-ITM2A and: PTCH1-eGFP or myr-
eGFP-CTD, pcDNA3.1 was used as control. 24 hours after transfection, cells 
were lysed and immunoprecipitated with anti-Myc antibody, followed by analysis 
of PTCH1-eGFP and myr-eGFP-CTD in the IP and whole cell lysate (input). B. 
HEK293 cells were transfected with Myc-ITM2A and PTCH1-eGFP or 
PTCH1∆ML-eGFP or PTCH1∆ML-∆CTD-eGFP,  pcDNA 3.1 was used as control. 
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24 hours after transfection, cells were lysed and immunoprecipitated with anti-
Myc antibody, followed by analysis of PTCH1-eGFP, PTCH1∆ML-eGFP and 
PTCH1∆ML-∆CTD-eGFP in the IP and whole cell lysate (input).  
 
5.3.2 ITM2A interacts with itself  
There is not much biochemical information available on ITM2A. To understand 
better this protein’s behaviour, it was decided to investigate if ITM2A could 
interact with itself. This is especially relevant for this study because PTCH1 is 
known to form functional dimers (Qi et al., 2018). HEK293 cells were co-
transfected with Myc-ITM2A, HA-ITM2A and empty vector as a control. Co- 
immunoprecipitation analysis showed that ITM2A can interact with itself (Figure 
5.3). It would be interesting to understand the oligomeric state of ITM2A as this 
can provide more information about its interaction with other proteins and how 
this interaction could be manipulated for therapeutic use. 
 
Figure 5.3 ITM2A physically interacts with itself 
HEK293 cells were transfected with Myc-ITM2A and HA-ITM2A, pcDNA 3.1 was 
used as control. 24 hours after transfection, cells were lysed and 
immunoprecipitated with anti-HA antibody, followed by analysis of Myc-ITM2A in 
the IP and whole cell lysate (input).  
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5.3.3 Co-expression of PTCH1 and ITM2A does not change the 
inhibition of autophagic flux by PTCH1  
Once the interaction between PTCH1 and ITM2A had been confirmed in 
mammalian cells, and considering that our previous work and the work of others 
shows that both ITM2A and PTCH1 block autophagy at the final step of the 
process (Chen et al., 2018; Namkoong et al., 2015), it was hypothesised that the 
interaction of PTCH1 with ITM2A could be necessary for the autophagy inhibition 
induced by PTCH1. HEK293 cells were transfected with ITM2A or PTCH1 alone 
or in combination. After 24 hours, cells were treated with BafA1 or DMSO to block 
autophagy, followed by western blotting of autophagy markers LC3B-II and p62. 
Results show that both proteins equally inhibit autophagic flux individually and no 
additive or synergistic effects are observed when both proteins are expressed 
together (Figure 5.4A-D). Strikingly, western blots showed that when ITM2A was 
overexpressed alongside PTCH1, the expression of PTCH1 was significantly 
downregulated (Figure 5.4E), which suggests that ITM2A could be affecting the 
stability of PTCH1 and promoting its degradation, and in this way ITM2A could 
be having an indirect effect on the autophagy block induced by PTCH1 by 
reducing the blocking effect of PTCH1.  
It is possible that the effect of PTCH1 on autophagy when co-transfected with 
ITM2A, is being underappreciated because the system is already saturated by 
ITM2A. Our results clearly show that ITM2A is causing a reduction on the protein 
expression of PTCH1. A decrease in PTCH1 expression potentially means a 
decrease in its autophagy flux blockade function. However, this reduction could 
be masked if either protein was maximally inhibiting autophagic flux. In addition, 
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if ITM2A is affecting the stability of PTCH1, this could indicate that ITM2A could 
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Figure 5.4 . Overexpression of ITM2A does not enhance the autophagic flux 
block induced by PTCH1 
A. Expression levels of p62 and LC3B-II in HEK293 cells transfected with 
pcDNA3.1, PTCH1-HA, Myc-ITM2A or both and cultured 24 hours in complete 
growth medium with or without the addition of 100nM Bafilomycin (BafA1) during 
the last 4 hours. Representative experiment of n=3.  B. Densitometric 
quantification of p62 western blot signals normalized to β-actin in comparison to 
pcDNA3.1 (n=3). C. Densitometric quantification of LC3B-II western blot signals 
normalized to β-Actin in comparison to pcDNA3.1 (n=3). D. Calculated values of 
autophagic flux using mean changes in LC3B-II levels normalised to  β-Actin with 
BafA1 over its level with vehicle (DMSO) for each condition (n=3). E. 
Densitometric quantification of PTCH1-HA western blot signals normalized to β-
Actin in comparison to pcDNA3.1 (n=3; * P < 0.05, *** P < 0.001). 
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5.3.4 Generation of stable HEK293 and HeLa cell lines with ITM2A 
knockdown  
As a complementary approach to ITM2A overexpression, and to completely 
understand if the autophagic flux blockade exerted by PTCH1 was mediated 
through its interaction with ITM2A, it was decided to deplete the cells of 
endogenous ITM2A. First, the mRNA endogenous levels of ITM2A in HEK293 
and HeLa cells were analysed by qPCR (Figure 5.5) because there were no 
commercial antibodies that can detect the low endogenous expression levels of 




Figure 5.5 Endogenous levels of ITM2A in HEK293 and HeLa cells 
A. ∆Ct values of ITM2A in HEK293 cells and HeLa cells,  normalised to GAPDH 
(duplicate). B. mRNA expression levels of ITM2A in HeLa cells relative to 
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The first approach to deplete endogenous levels of ITM2A involved transient 
silencing using siRNAs. For this, HEK293 and HeLa cells were transiently 
transfected with ITM2A siRNA or control MISSION siRNA to silence the 
expression of ITM2A. Transfection conditions were optimised to achieve the 
highest ITM2A knockdown maintained during 72 hours after transfection. The 
evaluation of the knockdown efficiency was carried out by RT-qPCR. However, 
the knockdown efficiency varied significantly among biological repeats. In 
HEK293 cells, the knockdown efficiency ranged between 0% and 66% (Figure 
5.6A). The silencing of ITM2A in HeLa cells was more efficient, although similarly 
variable, with knockdown efficiency between 38% and 97% (Figure 5.6B).  
 
 
Figure 5.6 ITM2A gene transcription after siRNA silencing 
A. mRNA expression levels of ITM2A in HEK293 cells relative to control MISSION 
siRNA. mRNA levels were normalised to GAPDH. B. mRNA expression levels of 
ITM2A in HeLa cells relative to control MISSION siRNA. mRNA levels were 
normalised to GAPDH. 
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To analyse if ITM2A mediates the autophagic flux blockade regulated by PTCH1, 
HEK293 cells and HeLa cells with knockdown of endogenous ITM2A for 48 hours, 
were transfected with PTCH1 and empty vector. After 24 hours of transfection 
with PTCH1 and a total of 72 hours of ITM2A knockdown, cells were treated with 
BafA1 to block autophagy followed by western blotting for PTCH1-HA and 
autophagy markers LC3B-II and p62 for HEK293 (Figure 5.7A) and HeLa 
(Figure 5.8A). Densitometric analysis of autophagy markers p62 (Figure 5.7B) 
and LC3B-II (Figure 5.7C) in HEK293, and for p62 (Figure 5.8B) and LC3B-II 
(Figure 5.8C) in HeLa were not conclusive as the biological repeats were highly 
variable. This could be attributed to the different knockdown efficiency obtained 
each time the siRNA ITM2A was transfected. However they suggest that ITM2A 
silencing does not affect the autophagic flux blockade exerted by PTCH1. 
Interestingly, there was a notable increase in the expression of PTCH1 in cells 
with silenced ITM2A, for both HEK293 cells (Figure 5.9A) and HeLa cells (Figure 
5.9B). The increase in the expression was more marked in HeLa cells, which 
presented a higher knockdown efficiency when compared to HEK293 cells. 
These results agree with the observations of the co-expression experiments, 
further suggesting that even endogenous ITM2A could be affecting PTCH1 
stability and therefore its ability to block autophagy.  
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Figure 5.7 Transient ITM2A silencing does not change the autophagy 
phenotype exerted by PTCH1 in HEK293 cells 
A. Expression levels of PTCH1-HA, p62 and LC3B-II in HEK293 cells with 
silenced ITM2A expression and transfected with pcDNA3.1 or PTCH1-HA and 
cultured 24 hours in complete growth medium with or without the addition of  100 
nM Bafilomycin (BafA1) during the last 4 hours. Representative experiment of 
n=2. B. Densitometric quantification of p62 western blot signals normalized to β-
Actin in comparison to pcDNA3.1 (n=2). C. Densitometric quantification of LC3B-
II western blot signals normalized to β-Actin in comparison to pcDNA3.1 (n=2).  
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Figure 5.8 Transient ITM2A silencing does not change the autophagy 
phenotype exerted by PTCH1 in HeLa cells 
A. Expression levels of PTCH1-HA, p62 and LC3B-II in HeLa cells with silenced 
ITM2A expression and transfected with pcDNA3.1 or PTCH1-HA and cultured 24 
hours in complete growth medium with or without the addition of  100 nM 
Bafilomycin (BafA1) during the last 4 hours. Representative experiment of n=2. 
B. Densitometric quantification of p62 western blot signals normalized to β-Actin 
in comparison to pcDNA3.1 (n=2). C. Densitometric quantification of LC3B-II 
western blot signals normalized to β-Actin in comparison to pcDNA3.1 (n=2). 
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Figure 5.9 Transient ITM2A silencing increases the expression of PTCH1 in 
HEK293 and HeLa cells 
HEK293 and HeLa cells with silenced ITM2A expression and transfected with 
pcDNA3.1 or PTCH1-HA and cultured 24 hours in complete growth medium with 
or without the addition of 100 nM Bafilomycin (BafA1) during the last 4 hours. A. 
Densitometric quantification of PTCH1-HA western blot signals of HEK293 in 
figure 4.7A normalized to 𝛽-Actin in comparison to control (n=2). B. Densitometric 
quantification of PTCH1-HA western blot signals of HeLa in figure 4.8A 
normalized to 𝛽-Actin in comparison to control (n=2).  
 
Considering the unexpected but significant results of the effect of ITM2A on the 
protein level of PTCH1, and because of the lack of consistent knockdown 
efficiency, it was decided to generate a stable cell line with shRNA  technology. 
HEK293 and HeLa cells were transfected with a mix of 3 shITM2A duplexes and 
selected with puromycin, however, as seen in the siRNA knockdowns, the ITM2A 
expression was restored after several passages (data not shown). This might be 
because as a heterogeneous population, cells expressing higher levels of ITM2A  
had a growth advantage and their proportion increased during passaging. 
Considering this, it was decided to generate stable single cell derived clones 
Chapter 5: Interaction of the CTD of PTCH1 with ITM2A: characteristics and effect on autophagy in HEK293 





containing shITM2A. HEK293 and HeLa cells were transfected with shITM2A, 
selected with puromycin and seeded using the limiting dilution method to obtain 
multiple clones with different knockdown percentages. However, the silencing 
was lost after cell passaging (data not shown). Therefore the next approach was 
to generate stable knockdown cells using lentiviral transduced shRNA ITM2A to 
successfully integrate the shRNA into the genomic DNA. First, each one of the 
three shRNAs found in the commercial human shRNA ITM2A was identified by 
Sanger sequencing and labelled shITM2A-A, shITM2A-B and shITM2A-C. 
HEK293T cells were transfected with each shITM2A to generate lentiviral 
particles. Media containing viral particles was used to infect HEK293 and HeLa 
cells and selected with puromycin to generate a stable cell line for each shITM2A 
sequence. Samples for different and consecutive passages were collected and 
the knockdown efficiency was measured by RT-qPCR. The shITM2A with the 
highest knockdown percentage maintained for at least three passages was 
identified for each cell line (Figure  5.10). For HEK293 it was the shITM2A-C with 
a minimum of 65% of knockdown efficiency. For HeLa, it was the shITM2A-B, 
with a minimum of 75% of knockdown efficiency.  
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Figure 5.10 . ITM2A gene transcription after shRNA silencing 
A. mRNA expression levels of ITM2A in HEK293 cells relative to shScramble. 
mRNA levels were normalised to GAPDH (n=3). B. mRNA expression levels of 
ITM2A in HeLa cells relative to shScramble. mRNA levels were normalised to 
GAPDH (n=3).  
 
 
5.3.5 ITM2A knockdown does not prevent the autophagic flux 
blockade phenotype induced by PTCH1 
Once the ITM2A knockdown stable cell lines were confirmed, they were used to 
study if ITM2A is a necessary mediator of the autophagic flux blockade regulated 
by PTCH1. HEK293 shITM2A-C and HeLa shITM2A-B were found to present  
and maintain the highest knockdown efficiency. These cells were transfected with 
Myc-PTCH1 or empty vector. After 24 hours, cells were treated with BafA1 to 
block autophagy followed by western blotting of Myc-PTCH1 and autophagy 
markers LC3B-II and p62. 
In HEK293 cells, the ITM2A knockdown did not impair the autophagic flux 
blockade regulated by PTCH1. Western blotting results of autophagy markers 
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show that  the blocking effect of PTCH1 in cells with silenced ITM2A expression 
is similar to the blocking effect of PTCH1 in scramble control (Figure 5.11A-C). 
Interestingly ITM2A silencing generated a slight increase in PTCH1 expression, 
however this increase was not statistically significant (Figure 5.11D).  
In HeLa cells, that have a higher knockdown efficiency, the effect of the 
knockdown on the autophagic flux blockade exerted by PTCH1 is more 
pronounced than in HEK293 cells. HeLa cells with silenced ITM2A were more 
susceptible to the effect of PTCH1 on autophagy, and therefore they presented 
an increased autophagic flux blockade when compared to scramble control 
(Figure 5.12A-C).  
It is possible that the effect of PTCH1 on autophagy increased in the knockdown 
cells, because, as the previously described results suggest, the expression of 
ITM2A affects the stability of PTCH1 and could be promoting its degradation. In 
the cells with silenced ITM2A,  PTCH1 has increases stability, and therefore its 
autophagy blocking phenotype is subsequently increased. 
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Figure 5.11 ITM2A knockdown does not prevent the autophagic flux 
blockade induced by PTCH1 in HEK293 cells 
A. Expression levels LC3B-II in HEK293 shScramble and HEK293 shITM2A-C 
cells transfected with pcDNA3.1 or Myc-PTCH1 (1-1447),  and cultured 24 hours 
in complete growth medium with or without the addition of  100 nM Bafilomycin 
(BafA1) during the last 4 hours. Representative experiment of n=3.  B. 
Densitometric quantification of LC3B-II western blot signals normalized to 
GAPDH in comparison to pcDNA3.1 (n=3). C. Calculated values of autophagic 
flux using mean changes in LC3B-II levels normalised to GAPDH with BafA1 over 
its level with vehicle (DMSO) for each condition (n=3; * P < 0.1, ** P < 0.05) 
 D. Densitometric quantification of Myc-PTCH1 western blot signals normalized 
to GAPDH in comparison to pcDNA3.1  (n = 3). 
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Figure 5.12 ITM2A knockdown does not prevent the autophagic flux 
blockade induced by PTCH1 in HeLa cells 
A. Expression levels LC3B-II in HeLa shScramble and HeLa shITM2A-B cells 
transfected with pcDNA3.1 or Myc-PTCH1 (1-1447),  and cultured 24 hours in 
complete growth medium with or without the addition of  100 nM Bafilomycin 
(BafA1) during the last 4 hours. Representative experiment of n=3.  B. 
Densitometric quantification of LC3B-II western blot signals normalized to 
GAPDH in comparison to pcDNA3.1 (n=3). C. Calculated values of autophagic 
flux using mean changes in LC3B-II levels normalised to GAPDH with BafA1 over 
its level with vehicle (DMSO) for each condition (n=3; *P<0.05). D. Densitometric 
quantification of Myc-PTCH1 western blot signals normalized to GAPDH in 
comparison to pcDNA3.1 (n=3). 
 
 
Notably, ITM2A-depleted HeLa cells displayed an increased basal autophagic 
flux, that could be the result of the ITM2A silencing as ITM2A blocks autophagy. 
The expression of PTCH1 is slightly higher in ITM2A knockdown cells, although 
not statistically significant (Figure 5.12D). 
 
Chapter 5: Interaction of the CTD of PTCH1 with ITM2A: characteristics and effect on autophagy in HEK293 





Finally, to confirm that the phenotype observed is generated by the silencing of 
ITM2A and not due to an off-target effect of the shRNA, it was decided to use the 
shITM2A with the second highest knockdown efficiency for both cell lines. For 
HEK293, shITM2A-B produced a knockdown efficiency of at least 21%. For HeLa, 
shITM2A-C generated a knockdown efficiency of at least 35%.  
The selected cells were transfected with Myc-PTCH1 or empty vector. After 24 
hours, cells were treated with BafA1 to block autophagy followed by western 
blotting of Myc-PTCH1 and autophagy markers LC3B-II and p62. On both, 
HEK293 and Hela cells, the results suggest the same phenotype as the one 
observed with the shITM2A that gave the highest knockdown efficiency (Figure 
5.13A&B). Western blotting results for autophagy markers show a slight increase 
in the PTCH1 blocking effect of autophagy after ITM2A silencing when compared 
to scramble control, suggesting that the ITM2A knockdown does not impair the 
autophagic flux blockade regulated by PTCH1. Also, western blotting results 
show a slight increase in PTCH1 expression in cells with silenced ITM2A. Is 
important to notice that these results were obtained with a single repeat.  
Taken together, these results show that ITM2A is not a mediator of the 
autophagic flux blockade regulated by PTCH1, in fact results suggest that the 
expression of ITM2A is causing the degradation of PTCH1 and in this way its 
expression might be causing a reduction on the autophagic flux blockade induced 
by PTCH1. 
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Figure 5.13 ITM2A knockdown does not impair the autophagic flux blockade 
induced by PTCH1 in HEK293 and HeLa cells 
Expression levels of p62, LC3B-II and Myc-PTCH1 in A. HEK293 shScramble 
and HEK293 shITM2A-B and B. HeLa shScramble and HeLa shITM2A-C 
transfected with pcDNA3.1 or Myc-PTCH1 (1-1447),  and cultured 24 hours in 
complete growth medium with or without the addition of 100 nM Bafilomycin 
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We also investigated if the ITM2A knockdown had any effect on HEK293 and 
HeLa cells doubling time. For each cell line the number of cells was counted at 
24, 48 and 72 hours after seeding. Stable shITM2A-expressig cells with the 
highest and second highest knockdown efficiency were compared to their 
respective scramble controls. In HEK293 cells, results show that ITM2A silencing 
does not affect the cell doubling rate when compared to control (Figure 5.14). In 
HeLa cells, results show that ITM2A knockdown caused a statistically significant 
decrease in the cell doubling rate of shITM2A-B cells from ~18 hours to ~12 hours 
(Figure 5.15). A potential reason for why the ITM2A silencing only affected HeLa 
cells, is that the knockdown efficiency in HeLa cells was higher than in the 
HEK293 cells. These results suggest that even low levels of ITM2A have a 
negative regulatory effect on expansion of HeLa cells, probably related to its 
effect as a negative regulator of the autophagic flux.  
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Figure 5.14 ITM2A partial silencing does not change the cell doubling rate 
of HEK293 cells 
Cells were cultured in complete growth medium, trypsinised and the number of 
cells counted using a haemocytometer chamber at 24 hours, 48 hours and 72 
hours A. HEK293 shScramble and HEK293 shITM2A-C (n=3). B. HEK293 
shScramble and HEK293 shITM2A-B (n=3). 
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Figure 5.15 ITM2A partial silencing decreases the cell doubling rate of HeLa 
cells 
Cells were cultured in complete growth medium, trypsinised and the number of 
cells counted using a haemocytometer chamber at 24 hours, 48 hours and 72 
hours A. HeLa shScramble and HeLa shITM2A-B (n=3). B. HeLa shScramble 
and HeLa shITM2A-C (n=3;  * P < 0.05, ** P < 0.01) 
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5.3.6 ITM2A inhibits the canonical Hh signalling pathway at the level 
of Gli1 and Gli2 
PTCH1 physically interacts with ITM2A. Interestingly, this interaction was first 
identified through the CTD, which mediates non-canonical Hh signalling, but 
results in the previous chapter later demonstrated that is not restricted to that 
domain. The previously presented results show that ITM2A is potentially 
interacting with the transmembrane regions and/or with the extracellular loops of 
PTCH1. Given that ITM2A interacts with other regions of PTCH1 involved in SMO 
regulation, it was hypothesised that ITM2A could be causing an important effect 
in the canonical Hh signalling. This hypothesis is further supported by the 
observation that, in the different cell lines used the overexpression of ITM2A 
appears to cause a downregulation of PTCH1 levels. ITM2A could potentially be 
reducing PTCH1 stability and promoting its degradation, affecting in this way the 
overall regulation of the canonical Hh signalling pathway.  
To investigate if ITM2A plays a role in canonical Hh signalling, the well-
established Gli-luciferase activity assay was used. The assay was performed in 
NIH3T3 cells, which are the best characterised model to study canonical Hh 
signalling. Results show that the expression of ITM2A does not affect the 
activation of Gli-luciferase when the pathway was stimulated by co-expression of 
Shh or an oncogenic mutant SmoM2 (that is active even in the presence of 
PTCH1). However, a non-significant increasing trend was present, perhaps 
reflecting an additive effect over endogenous Ptc1 levels. In addition, ITM2A 
expression did not ectopically increase basal Gli-luciferase in the absence of a 
specific stimulus. pSV40-Renilla was used for normalisation purposes (Figure 
5.16A). However, when ITM2A was co-expressed with Gli1 and Gli2, it displayed 
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a strong inhibitory effect. Given the unexpected finding of a “distal” effect of 
ITM2A, a plasma membrane protein, on soluble cytosolic/nuclear Gli transcript 
factors, the experiment was repeated again with a different normalisation 
reporter. The pRL-TK construct expressing Renilla luciferase from the promoter, 
was also used instead of the pRL-SV40 construct, which expresses Renilla 
luciferase under the control of the strong SV40 promoter. Similar results were 
observed, confirming the validity of our findings (Figure 5.16B).  
An additional control was performed to determine if the inhibitory effect of ITM2A 
on Gli1 and Gli2 was dependent on its interaction with PTCH1. Using Ptc1-/- 
mouse embryonic fibroblast (MEFs) cells, which have a constitutively active 
canonical Hh signalling as they are deficient in Ptc1, the Gli-luciferase assay 
showed that ITM2A can inhibit Gli1 and Gli2 transcriptional activity in the absence 











Chapter 5: Interaction of the CTD of PTCH1 with ITM2A: characteristics and effect on autophagy in HEK293 






Figure 5.16 Overexpression of ITM2A inhibits Gli1 and Gli2 transcriptional 
activity in NIH3T3 cells 
Gli-luciferase activity was measured in NIH3T3 cells co-transfected with the 
promoter reporter constructs A. pSV40 and B. pRL-TK and plasmids pcDNA3.1, 
Myc-ITM2A, Shh, SmoM2, Gli1 and Gli2 (as specified). After 24 hours, cells were 
changed to serum starvation media and incubated for 24 additional hours. Cells 
were harvested and luciferase activity was determined using the Dual-Luciferase 
Reporter Assay System (Promega) according to manufacturer’s instructions 
(n=3;  * P < 0.05). 
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Figure 5.17 Overexpression of ITM2A inhibits Gli1 and Gli2 transcriptional 
activity in Ptc1-/- MEFs cells 
Gli-luciferase activity was measured in Ptc1-/- MEFs cells co-transfected with the 
promoter reporter construct pRL-SV40 and plasmids pcDNA3.1, Myc-ITM2A, 
Shh, SmoM2, Gli1, Gli2 and Gli3 (as specified). After 24 hours, cells were 
changed to serum starvation media and incubated for 24 additional hours. Cells 
were harvested and luciferase activity was determined using the Dual-Luciferase 
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5.4 Discussion  
ITM2A and PTCH1 exert the same autophagy blocking phenotype characterised 
by an accumulation of autophagosomes (Namkoong et al., 2015; Chen et al., 
2018). The results presented in this chapter show that ITM2A and PTCH1 
physically interact with each other. However, their interaction is not necessary for 
the autophagic flux blockade induced by PTCH1 in HEK293 and HeLa cells. 
Results suggest that each protein, individually and through a potentially different 
mechanism, blocks autophagy at the last step of the process. Furthermore, our 
results also show that ITM2A indirectly affects the biological function of PTCH1 
by reducing its stability. Therefore, ITM2A is not a mediator of the autophagic flux 
blockade regulated by PTCH1, but instead reduces its activity, while still 
maintaining its capacity to block autophagy independently of the interaction.  
Our results clearly show that ITM2A has an important consequence on the 
expression of PTCH1. Even when the change in the expression of PTCH1 in the 
ITM2A knockdown cells was not statistically significant, the slight increase in 
PTCH1 expression was enough to enhance its inhibitory effect on autophagy. It 
is possible that the effects on the knockdown are not as marked as the effects of 
the overexpression because the endogenous levels of ITM2A in HEK293 and 
HeLa are low, and also because the efficiency of the knockdown was not 100%. 
This is supported by the observation that, when comparing the effects in the two 
cells lines, the results are statistically significant in HeLa cells, which presented 
a higher knockdown efficiency. 
Of great importance as well, were the findings that ITM2A not only interacts with 
the CTD of PTCH1 and that the interaction with this region can only occur when 
the CTD is membrane bound. As ITM2A is a single pass transmembrane protein, 
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and we first hypothesised that the interaction occurs with the intracellular N-
terminus, which is only 53 amino acids long, close proximity in the plasma 
membrane could be important for the interaction. Unexpectedly, our results show 
that ITM2A maintained the interaction with a mutant of PTCH1 without the CTD 
and with a double mutant without the intracellular middle loop and without the 
CTD, which suggest that ITM2A could also be interacting with the transmembrane 
regions or extracellular domains of PTCH1 through ITM2A’s BRICHOS domain.  
Overall, these results are of great importance as further strengthen the 
hypothesis that the main effect of ITM2A in the Hh signalling pathway is not as a 
mediator of the autophagic flux blockaded regulated by PTCH1 categorised in the 
Hh non-canonical signalling. Instead ITM2A involvement in the Hh signalling 
could be occurring through regulation of PTCH1 levels and by altering the activity 
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Chapter 6                                                                               
Role of Itm2a on autophagic flux regulation during 
myogenic differentiation  
6.1 Introduction 
Different studies have shown  that the specific role of ITM2A varies depending on 
the cell type (Van den Plas and Merregaert, 2004a; Van den Plas and Merregaert, 
2004b; Tai et al, 2014). Therefore, it is possible that the impact of its expression 
would be more relevant in cells with higher endogenous levels of Itm2a, such as 
skeletal muscle cells. The murine skeletal myoblast C2C12 cell line was 
established from myoblasts obtained 70 hours after crush injury in the thigh 
muscle of a 2-month-old C3H mouse (Yaffe and Saxel, 1977). The expression of 
Itm2a is upregulated during differentiation of C2C12 cells into myotubes. Higher 
expression levels of Itm2a are related to an earlier appearance of the 
morphological changes associated with myotube formation and to a faster 
achievement of terminal differentiation. However, it was reported that the 
expression of Itm2a does not exert any effect in myoblast proliferation rate (Van 
den Plas and Merregaert, 2004a; Lagha et al., 2013). The C2C12 cell line is 
commonly used to study myogenic differentiation as its differentiation is easily 
induced in a reproducible and time-dependent manner. C2C12 myoblasts 
proliferate in the presence of high serum (10% FBS) at low medium density and 
are induced to differentiate into fully mature myotubes by partially withdrawing 
the serum from the culture medium (2% horse serum) at high confluence (Van 
den Plas and Merregaert, 2004a) (Figure 6.1).  
 







Figure 6.1 Simplified schematic representation of C2C12 myogenic 
differentiation 
C2C12 cells are kept as proliferative myoblasts in complete media supplemented 
with 10% FBS. The induction of differentiation is carried out once myoblast reach 
confluence by switching the complete media to differentiation media containing 
2% horse serum. Differentiating myoblast fuse with each other to form 
differentiated myotubes. Created with BioRender.com. 
 
 
A recent study showed that Itm2a plays a role in the regulation of key myogenic 
transcription factors, as Itm2a knockdown caused a decrease in the expression 
of MyoD, myogenin and myosin light chain (MYL2) in C2C12 cells during 
differentiation (Lee et al., 2018). Muscle-specific transcription factors MyoD and 
Myf5 are expressed in proliferating myoblasts, upon induction of differentiation 
the expression of Myf5 is downregulated and the upregulation of myogenin is 






observed after cell cycle withdrawal (Lee, 2002). Therefore, as exit of the cell 
cycle is required, skeletal muscle differentiation involves the interaction between 
myogenic factors and cell cycle regulators (Hwang et al., 2015; Lee, 2002). The 
progression of the cell cycle, in eukaryotes, relies in the expression (in an orderly 
fashion) of cyclin-dependent kinases (CDKs), cyclins and CDK inhibitors (CDKIs). 
CDKs are activated by cyclins and negatively regulated by CDKIs (Franklin and 
Xiong, 1996). D-type cyclins (D1, D2 and D3), form complexes and activate CDK4 
and CDK6 in the G1 phase of the cell cycle to promote cell proliferation (Duronio 
and Xiong, 2013). The expression of D-type cyclins is regulated by the presence 
of growth factors and during proliferation they share similar functions in different 
cell types. However, it has been suggested that upregulation of cyclin D3 is a 
requisite for myogenic differentiation (Bartkova et al., 1998; Cenciarelli et al., 
1999).   
The C2C12 cell line is particularly relevant to this study because it has been used 
to study the role of Hh signalling in skeletal muscle. Shh promotes proliferation of 
C2C12 myoblasts, inhibiting terminal differentiation and, in this way, opposing the 















6.2 Aims  
To study if reported changes of Itm2a expression during skeletal muscle cell 
differentiation regulate the autophagic flux during the process, the last part of my 
research was aimed at:  
 Investigating the consequences of Itm2a knockdown on C2C12 myoblast 
proliferation and differentiation. 
 Understanding the consequences of Itm2a knockdown on basal 
autophagy in C2C12 myoblasts. 























6.3 Results  
6.3.1 Characterisation of Itm2a expression during C2C12 cells 
differentiation 
Considering that the effects of Itm2a are cell-type specific and that it has been 
shown that during myogenic differentiation of C2C12 cells an increase in the 
expression levels of Itm2a is observed (Van den Plas and Merregaert, 2004a: 
Lee et al., 2018). It was firstly decided to establish the differentiation conditions 
for the C2C12 cell line. Myogenic differentiation of the C2C12 cell line was 
examined by their morphological changes. As expected, during the differentiation 
process the mononucleated and spindle-like shape myoblasts aligned, elongated 
and fused together to form multinucleated myotubes (Figure 6.2A-H). Maximal 
differentiation accompanied by spontaneous contractions of myotubes was 
observed after 7 days of differentiation. 
When C2C12 cells differentiate, myoblasts become mature myotubes by 
undergoing a remodelling process that is accompanied by the expression of 
muscle-specific proteins and proteins involved in cell fusion. Myosin heavy chain 
(MHC) is a structural protein highly expressed in myotubes, and therefore a 
specific marker for myotubes and differentiation (Hwang et al., 2015; Tang et al., 
2018). C2C12 cells were induced to differentiate by serum switch, and whole cell 
lysates were prepared along each day of the process, from day 0 to day 7. 
Expression of MHC, as a marker for differentiation, was analysed by western 
blotting (Figure 6.3). The changes in protein and mRNA expression of Itm2a were 
analysed throughout the 7 days of differentiation in C2C12 cells (Figure 6.4A&B). 
Additionally, the changes in mRNA expression of Ptc1 during myogenic 
differentiation  were also analysed by qPCR (Figure 6.5). 







Figure 6.2 Myogenic differentiation of C2C12 cells 
C2C12 were cultured in differentiation media for 7 days. Differentiation media was added to cells at day 0 and changed to fresh 
differentiation media every other day. A. Day 0. B. Day 1. C. Day 2. D. Day 3. E. Day 4. F. Day 5. G. Day 6. H. Day 7.  
 







Figure 6.3 Myosin heavy chain expression is upregulated during myogenic 
C2C12 cells differentiation 
Expression levels MHC in C2C12 cells during 7 days of differentiation. 
Differentiation media was added to cells at day 0 and changed to fresh 
differentiation media every other day. Representative experiment of n=3.   
 
Figure 6.4 Itm2a expression during myogenic differentiation of C2C12 cells 
A. mRNA expression levels of Itm2a in C2C12 cells during differentiation. mRNA 
levels were normalised to GAPDH (n=3). B. Expression levels Itm2a in C2C12 
cells during 7 days of differentiation. Representative experiment of n=3. 
Differentiation media was added to cells at day 0 and changed to fresh 
differentiation media every other day.   







Figure 6.5 Ptc1 expression during myogenic C2C12 cells differentiation 
mRNA expression levels of Ptc1 in C2C12 cells during differentiation. mRNA 
levels were normalised to GAPDH (n=3). Differentiation media was added to cells 
at day 0 and changed to fresh differentiation media every other day.   
 
 
6.3.2 Generation of stable C2C12 cells with shRNA-mediated 
silencing of Itm2a 
To investigate the role of Itm2a in the myogenic differentiation process, it was 
decided to generate stable itm2a-shRNA C2C12 cells by lentiviral transduction 
followed by selection of cells resistant to puromycin. A commercial shRNA 
plasmid mix targeting itm2a contained three plasmids with different shRNA 
sequences. An initial attempt showed insufficient knockdown, which prompt us to 
isolate and sequence each plasmid (shItm2a-A, shItm2a-B and shItm2a-C) were 
sequences for individual use. HEK293T cells were transfected with each single 

























































and Methods chapter, to generate individual lentiviral particles targeting Itm2a. 
C2C12 cells were infected with HEK293T supernatant containing the viral 
particles and selected with puromycin to generate a stable cell line for each 
shItm2a duplex. Control shRNA C2C12 cells were generated in a similar manner 
using control shRNA Plasmid-A (shScramble). Samples from different passages 
were collected to establish the knockdown efficiency by qPCR and its stability 
over time. None of the individual shRNAs achieved a very high knockdown 
efficiency. shItm2a-C displayed the highest knockdown efficiency (<40%) in 
undifferentiated cells maintained for at least three passages (Figure 6.6) and 
was, thus, selected for future experiments, under the assumption that we would 
expect to see relatively minor effects.  
 
 
Figure 6.6 Itm2a gene transcription after shRNA silencing 
mRNA expression levels of Itm2a in C2C12 cells relative to shScramble. mRNA 

















































6.3.3 Autophagy modulation during skeletal muscle differentiation 
Given that ITM2A regulates autophagic flux in HEK293 and HeLa cells and it is 
upregulated during myogenic differentiation, it was decided to investigate 
changes on basal autophagic flux during C2C12 differentiation. Protein samples 
were collected from day 0 to day 7 of differentiation. Four hours before protein 
extraction, BafA1 or DMSO was added to the cells. Lysates were analysed by 
western blotting for relative levels of autophagy markers LC3B-II and p62 (Figure 
6.7A,C&D). The overall levels of p62 and LC3B-II increased during 
differentiation, although becoming progressively more insensitive to the activity 
of BafA1. Calculation of autophagy flux showed progressive inhibition of the basal 
autophagic flux during differentiation of C2C12 cells (Figure 6.7E). This is in 
agreement with a potential inhibitory function of Itm2a on autophagic flux during 















Figure 6.7 Reduction of basal autophagic flux during C2C12 cell 
differentiation 
A. Expression levels of p62 and LC3B-II in C2C12 cells during 7 days of 
differentiation day with or without the addition of  100 nM Bafilomycin (BafA1) 
during the last 4 hours. Representative experiment of n = 3. B. Expression levels 
of myosin in C2C12 during 7 days of differentiation. Differentiation media was 
added to cells at day 0 and changed to fresh differentiation media every other. 
Representative experiment of n=3. C. Densitometric quantification of p62 western 
blot signals normalized to β-actin in comparison to pcDNA3.1 (n=3). D. 
Densitometric quantification of LC3B-II western blot signals normalized to β-actin 
in comparison to pcDNA3.1 (n=3).E. Calculated values of autophagic flux using 
mean changes in LC3B-II levels normalised to β-Actin with BafA1 over its level 
with vehicle (DMSO) for each condition (n=3). 






6.3.4 Effect of PTCH1 on autophagic flux in control and itm2a-
silenced C2C12 cells 
Next, C2C12 myoblasts with partially silenced Itm2a expression were used to 
understand the ability of PTCH1 to regulate autophagic flux in undifferentiated 
cells. C2C12 shItm2a-C cells and C2C12 shScramble control were transfected 
with Myc-PTCH1 or empty vector for 24 hours and treated with BafA1 or DMSO 
for 4 hours before protein extraction. Western blotting of autophagy markers 
LC3B-II and p62 was carried out (Figure 6.8A). Unexpectedly, results show that 
the overexpression of PTCH1 in the C2C12 shScramble myoblasts did not evoke 
the autophagic blockade phenotype previously described in HEK293 and HeLa 
cells (Chen et al., 2018). LC3B-II levels were not changed with PTCH1 
overexpression (Figure 6.8C) while there was only a moderate accumulation of 
p62 after overexpression of PTCH1 (Figure 6.8B). Remarkably, the silencing of 
Itm2a seemed to slightly restored the blocking effect of PTCH1 on autophagy 
(Figure 6.8B-D), albeit not to the same extent as previously described for 
HEK293 and HeLa cells (Chen et al., 2018). The same slightly restoring of the 
phenotype was observed in C2C12 shItm2a-B cell line after PTCH1 
overexpression (Figure 6.8F). However, there were technical problems with the 
p62 antibody and the blot could not be obtained.   
Interestingly, the expression of PTCH1 in C2C12 shItm2a-C cells was lower than 
in the scramble control cells although not significantly different (Figure 6.8E).  
These results suggest that Itm2a is negatively regulating the activity of PTCH1 in 
C2C12 cells or, alternatively, that the presence of high levels of Itm2a makes the 
effect of PTCH1 on autophagy negligible. 
 



















Figure 6.8 Itm2a silencing slightly restores the blocking effect of PTCH1 on 
autophagy in C2C12 myoblasts 
A. Expression levels of Myc-PTCH1, p62 and LC3B-II in C2C12 shScramble and 
C2C12 shITM2A-C cells transfected with pcDNA3.1 or Myc-PTCH1 (1-1447), and 
cultured 24 hours in complete growth medium with or without the addition of 100 
nM Bafilomycin (BafA1) during the last 4 hours. Representative experiment of 
n=3. B. Densitometric quantification of p62 western blot signals normalized to 
GAPDH in comparison to pcDNA3.1 (n=3). C. Densitometric quantification of 
LC3B-II western blot signals normalized to GAPDH  in comparison to pcDNA3.1 
(n=3). D. Calculated values of autophagic flux using mean changes in LC3B-II 
levels normalised to GAPDH with BafA1 over its level with vehicle (DMSO) for 
each condition (n=3). E. Densitometric quantification of Myc-PTCH1 western blot 
signals normalized to GAPDH in comparison to pcDNA3.1 (n=3). F. Expression 
levels of Myc-PTCH1 and LC3B-II in C2C12 shScramble and C2C12 shItm2a-B 
cells transfected with pcDNA3.1 or Myc-PTCH1 (1-1447), and cultured 24 hours 
in complete growth medium with or without the addition of 100 nM Bafilomycin 











6.3.5 Reduction of endogenous Itm2a levels delays the myotube 
differentiation process  
To understand the effects of Itm2a knockdown in C2C12 cells, stable shItm2a-C 
and shScramble C2C12 cells were induced to differentiate by switching to 
differentiation media. The effect of Itm2a silencing on the morphology of the cells 
was evaluated daily throughout the 7 days of the differentiation process (Figure 
6.9). Morphologically, differentiation is characterised by the loss of the myoblasts’ 
spindle-like shape and the formation of multinucleated myotubes of elongated 
shape (Hwang et al., 2015). Results showed that the appearance of 
morphological changes associated with myogenic differentiation is delayed in the 
cell line with reduced expression of Itm2a. Despite the initial delay in 
differentiation, after 7 days both, stable shItm2a-C and shScramble C2C12 cells, 
exhibited mature multinucleated myotubes. Our findings are in agreement with 
an independent study that reported that overexpression of Itm2a in C2C12 cells 
accelerated the formation of myotubes (Van den Plas and Merregaert, 2004a). 
The results presented in this chapter indicate that high levels of Itm2a are 
required for timely differentiation, with partial silencing delaying the differentiation 
process. These results should be observed with caution as the knockdown 
efficiency obtained during the 3 passages was at least 40% at the mRNA level. 
Therefore a higher knockdown efficiency would allow to discern if Itm2a 
knockdown could prevent differentiation. Experiments using the CRISPR/Cas9 
technology to knockout Itm2a would allow the validation of the presented findings.  
 
 







Figure 6.9 Myogenic differentiation of C2C12 cells with stable silencing of Itm2a 
C2C12 shItm2a-C and C2C12 shScramble control were induced to differentiate by switching complete media to differentiation media. 
Images were obtained from day 0 to day 7 of differentiation. Media was added to cells at day 0 and changed to fresh differentiation media 
every other day.  






The morphological changes in differentiation were confirmed  by analysing  the 
expression of MHC (Figure 6.10). Protein samples from C2C12 shItm2a-C and 
shScramble control were collected from day 0 to day 7 of differentiation and 
analysed by western blot. shItm2a-C cells expressed lower levels of itm2a, as 
expected. Results show that there is a delay in the expression of MHC in C2C12 
shItm2a-C compared to control cells. MHC expression appears on day 3 of 
differentiation in the shItm2a-C cells, while the expression of MHC in shScramble 
control appears on day 2 (Figure 6.10). Delay in the expression of MHC was also 
observed in the C2C12 shItm2a-B cells when compared to shScramble (data not 
shown). Even though both shItm2a-C and shItm2a-B presented a delay in the 
expression of MHC, the downregulation of MHC is more marked in the shItm2a-
C cells than in the shItm2a-B cells. This difference could be attributed to the 
previously indicated differences in knockdown efficiency.   
Protein samples were then used to study the changes in the expression of cyclin 
D3, a key regulator during cell cycle exit during myoblast differentiation (Gurung 
and Parnaik, 2012). Differentiation of the C2C12 myoblast cell line requires that 
the proliferative cells exit the cell cycle and remain arrested in the G1 phase, this 
is regulated by changes in the expression of cyclins, CDKs and CDK inhibitors 
(CDKIs). Cell cycle withdrawal allows differentiation and fusion of myoblasts to 
form myotubes (Walsh and Perlman,1997; Perry and Rudnick, 2000). During 
myogenic differentiation the expression levels of cyclin cyclin D1 are 
downregulated, while the expression levels of cyclin D3 increases upon 
differentiation, this upregulation of cyclin D3 is key for the cell cycle arrest 
required for the differentiation of myoblasts into myotubes (Cenciarelli et al., 
1999; Gurung and Parnaik, 2012; Pavlidou et al., 2017). Studies suggest that 






higher expression levels of cyclin D3 are related to faster differentiation kinetics 
through transcription of Pax7, and that differentiated myotubes express higher 
levels of cyclin D3 when compared to undifferentiated myoblasts. Studies have 
also shown that overexpression of cyclin D3 is accompanied with an increase in 
the expression levels of the CDKI p21 (Gurung and Parnaik, 2012). As previously 
mentioned, CDKIs regulated the progression of the cell cycle by negatively 
regulating the activity of CDKs. CDKIs exert their function by interacting directly 
with CDKs (before they interact with cyclins) or by interacting with the CDK-cyclin 
complexes causing their inactivation. p21 has an important role in regulation of 
the C2C12 cell cycle progression. Studies suggest that p21 allows the initiation 
of differentiation. However, its expression is not necessary to maintain the cell 
cycle arrest. Furthermore, p21 silencing does not disrupt cell cycle exit and does 
not block the differentiation into myotubes because of its functional redundancy 
with other inhibitors (Perlman, 1997; Walsh and Perlman, 1997; Cenciarelli et al., 
1999; Williamson et al., 2009; Pavlidou et al., 2017).  
In accordance to the phenotypic findings that Itm2a silencing produces a delay in 
myogenic differentiation, the expression levels of cyclin D3 did not increase until 
the final days of differentiation in C2C12 shItm2a-C cells when compared to 
C2C12 shScramble control cells. The expression levels of cyclin D3 in shItm2a-
C cells steadily and moderately increased during differentiation, while the level of 
cyclin D3 in shScramble cells plateaued after day 3 and then maintained 
throughout differentiation (Figure 6.10). 
Taken together, these results suggest that Itm2a has a role in the kinetics of 
myogenic differentiation by regulating cell cycle progression and, possibly, 
autophagy. It is possible that Itm2a knockdown in the C2C12 cells causes a 






change in the timing of the cell cycle withdrawal which delays, but not abolishes, 
the formation of fully differentiated myotubes. However, the specific regulatory 
mechanisms involved in the changes of the cell cycle induced after Itm2a 
silencing need to be further analysed. 
 
Figure 6.10 Cell cycle marker expression during differentiation of C2C12 
cells 
Expression levels of MHC, endogenous Itm2a, cyclin D3 and GAPDH in C2C12 
shItm2a-C and C2C12 scramble control during 7 days of differentiation. 
 
 
6.3.6 Itm2a silencing does not affect the cell doubling time in C2C12 
myoblasts  
It has been reported that overexpression of Itm2a in the C2C12 cell line does not 
change its doubling rate (Van den Plas and Merregaert, 2004a). However, the 
effect of Itm2a silencing in the cell division rates of C2C12 myoblasts has not 
been studied. Therefore, stable shItm2a-expressig cells with the highest and 
second highest knockdown efficiency were compared to scramble control to 
analyse the effect of Itm2a knockdown on myoblast expansion rate. Cells were 
seeded at low confluence on complete media (10% FBS) and trypsinised and 
counted at 24, 48 and 72 hours after seeding (Figure 6.11). Results show that 






Itm2a silencing in C2C12 myoblast does not affect the cell doubling rate when 
compared to control.  
 
 
Figure 6.11 Itm2a silencing does not affect the doubling time of C2C12 
myoblasts 
Cells were cultured in complete growth medium, trypsinised and the number of 
cells counted using a haemocytometer chamber at 24 hours, 48 hours and 72 
hours A. C2C12 shScramble and C2C12 shItm2a-C (n=3). B. C2C12 shScramble 
and C2C12 shIym2a-B (n=3). 






6.3.7 Identification of additional ITM2A-interacting proteins by mass 
spectrometry 
To identify new interacting partners of ITM2A that would help understand its 
function, HEK293 cells were transfected with HA-ITM2A or empty vector followed 
by immunoprecipitation after 24 hours using anti-HA. HEK293 cells were used 
due to their high transfection efficiency, although it is likely that muscle-specific 
proteins will not be expressed. Immunoprecipitates of ITM2A and a control with 
empty vector were sent proteomic analysis to the mass spec facility at the 
University of Leeds. Table 6.1 lists the proteins identified as present solely in 
ITM2A immunoprecipitates.  
The identification of ITM2A interacting proteins is relevant for this study as it can 
provide a better understanding of the mechanistic basis of specific process 
affected by ITM2A, in particular autophagy, cell cycle regulation and Hh 
signalling. Is important to consider that protein-protein interactions might vary in 
different cell types and can change as a response to modifications in the cellular 
environment (Richards et al., 2021). Therefore, the proteomic analysis in HEK293 
cannot be directly extrapolated to other cell types, and might not reveal the extent 
of potential binding partners in C2C12 cells. Nonetheless, this analysis is the first 
step towards the identification followed by the validation of novel protein 
interactions, and further along the line would be the analysis of the functional 
consequences of the validated interactions in more relevant models of study.  
The identified proteins show interaction with enrichment in endocytic machinery, 
DNA repair and ribosomal proteins. Potential nuclear localisation of ITM2A 
cytosolic domain is suggested by the types of interacting proteins. This could 
explain the strong effects on Gli1 and Gli2-mediated transcription. In addition, 






identification  of CDK2 inhibitor 2A (CDKN2A), also known as p16INK4 points to 
potential mechanistic basis for modulation of cell cycle progression.  
Mass spectrometry analysis was also used to identify the post-translational 
modifications of ITM2A (Figure 6.12).  The N-terminal domain, composed of the 
first 53 amino acids of the protein, was of interest of this analysis as we 
hypothesised that this region is key for ITM2A interaction with the CTD of PTCH1. 
Post-translational modifications can change the protein structure and in this way 
the properties of the protein and its biological function. They also play a role in 
how the protein of study interacts with other proteins (Wang et al., 2014). 
Therefore, the analysis of the post-translational modifications can be used as a 
first approach for the identification of the potential regions that could be 
manipulated. Mutations in specific regions can be used to further study the 
functions of ITM2A and the functional consequences of its interaction with other 
proteins to regulate cellular processes, such as proliferation and differentiation, 
or to study its involvement in signalling pathways, such as the Hh pathway. 
Results obtained show that a phosphorylation event of interest in the N-terminal 
region of ITM2A, which could affect its interaction with PTCH1 and modulate its 
function. Further studies will be necessary to investigate this further.  
  
Protein name Function UniProtKB 
identifier 
ABCF2 ATP-binding cassette sub-family F 
member 2 
Q9UG63 
ACTG1   Structural constituent of cytoskeleton P63261 
ADAR Adenosine deaminase, RNA editing P55265 
ALB Albumin P02768 
ATAD3A Mitochondrial network organization Q9NVI7 






ATP2A2 ER-isolation membrane contacts, 
autophagosome formation 
P16615 
ATP5F1C Mitochondrial membrane ATP 
production 
P36542 
ATXN2L Stress granule and P-body formation Q8WWM7 
BAG2 Co-chaperone for HSP70/HSC70 O95816 
C1orf57 
 
Nucleotide phosphatase Q5TDE9 
CANX ER protein folding quality control P27824 
CDK1 Cell cycle progression P06493 
CDKN2A Negative regulator of proliferation P42771 
CISD2 Regulator of autophagy Q8N5K1 
CSE1L 
 
Nuclear export receptor P55060 
DARS Aspartate tRNA-ligase P14868 
DNAJA1 
 
Co-chaperone of HSC70, mitochondria 
protein transport 
P25685 
DNAJA2 Co-chaperone of HSC70 O60884 
EEF1G Elongation factor P26641 
EIF4A1 Eukaryotic initiation factor P60842 
ERLIN2 Endoplasmic reticulum-associated 









Keratin intermediate filament 
aggregation 
P20930 
FLNA Branching of actin filaments P21333 
FLNC Muscle-specific filamin Q14315 
G3BP2 Stress granule formation Q9UN86 
GANAB Neutral alpha-glucosidase Q14697 
GP96 ER-chaperone, ERAD P14625 





ER-localised fatty acid elongation Q53GQ0 
HSPA1B HSP70 chaperone P0DMV9 
HSPA5 ER chaperone P11021 
LMAN1 ER to Golgi transport P49257 






MARS Methionine-tRNA ligase A0A024RBA2 
NPM1 
 





RNA-C5 methyl transferase, tRNA 
stability, mRNA decay 
Q08J23 
NUP93 Nuclear pore complex Q8N1F7 
PAI-1 Serine protease inhibitor P05121 
PGAM5 Mitochondrial dynamics Q96HS1 
PHB 
 





Mitochondrial chaperone, mitophagy 
receptor 
Q99623 
PSMD3 Component of the 26S proteasome O43242 
RALY 
 
Transcriptional cofactor for 
cholesterogenesis 
Q9UKM9 
RCN Post-ER calcium regulatory protein Q15293 






Table 6.1 Proteins identified by mass spectrometry in ITM2A 
immunoprecipitates 
This table shows the proteins identified by mass spectrometry, with details of their 















Figure 6.12 Mass spectrometry analysis of ITM2A immunoprecipitates 
Top: Legend for the identified post translational modifications. Bottom: Amino acid sequenced of ITM2A with identified post translational 
modifications. Sample was digested with trypsin. Blue lines represent the coverage.  
 
 






STRING analysis reveals a highly significant clustering (p= 1 x10-16) of over 90% 
of the proteins identified (Figure 6.13), with the existence of sub-clusters related 
to the ER protein quality control, mitochondria membrane protein translocation 
and stress granules. Some of the proteins identified play important roles in the 
recognition of defective mitochondria for clearance by mitophagy (prohibitin and 
prohibitin-2, ADACT3, HSPA1B). This snapshot of ITM2A interactome suggest 
that it might function at ER-mitochondria contacts to regulate mitophagy. This 
selective type of autophagy has been shown to play an important role during 
mitochondrial network remodelling in myogenic differentiation and could explain 
the regulatory role of Itm2a in C2C12 cells (Baechler et a;., 2019). 







Figure 6.13 Unsupervised STRING clustering of proteins identified in ITM2A 
immunoprecipitates from HEK293 cells 
The number of connecting lines increases with experimental evidence of physical 
or functional interaction. Known interactions=light blue and pink lines; predicted 
interactions=green, red and dark blue; textmining=yellow; co-expression=black; 
protein homology=purple (Szklarczyk et al., 2019). 
 
 






6.4 Discussion  
6.4.1 ITM2A effect in PTCH1 expression 
The results presented in the previous chapter show that expression of ITM2A 
downregulates PTCH1 levels, suggesting that it reduces its stability. Considering 
that ITM2A expression is affecting PTCH1 stability, it was no surprise that in the 
C2C12 cells that have a higher expression of endogenous ITM2A, the 
endogenous levels of ITM2A were sufficient to inhibit the autophagy phenotype 
observed when PTCH1 is transfected in HEK293 and HeLa cells (Chen et al, 
2018). When C2C12 cells with reduced ITM2A levels were transfected, the 
overexpression of PTCH1 generated the  previously described blocking effect on 
the autophagic flux, although not to the extent seen in HEK293 and HeLa cells 
(Chen et al, 2018). It is important to consider that the knockdown efficiency 
obtained for the C2C12 cell line was only 40% at an mRNA level.    
These results strengthen the hypothesis that the expression of ITM2A has a 
negative effect on the stability of PTCH1, causing its degradation.  
 
6.4.2 Cell cycle regulation by ITM2A 
Myoblasts express genes from the bHLH family of transcription factors, which 
mediate the expression of muscle specific genes upon induction of differentiation. 
Alongside the gene expression, cells also exit the cell cycle permanently (Franklin 
and Xiong, 1996; Williamson et al., 2009). Although the regulation of the muscle-
specific gene expression has been widely studied, there is still much left to 
uncover about the cell cycle withdrawal which is necessary for the initiation and 
maintenance of differentiation (Franklin and Xiong, 1996).  D-type cyclins act in 
the G1 phase of the cell cycle and they have the same interacting capacity with 






CDK4 and they all can activate it at the same degree in vitro during cellular 
proliferation. However, studies show that cyclin D3 also plays a role during 
myogenic differentiation. On the contrary to cyclin D1 and cyclin D2, the 
expression levels of cyclin D3 increase upon differentiation induction (Bartkova 
et al., 1998; Cenciarelli et al., 1999). Results presented in this chapter show that, 
when Itm2a expression is partially silenced in C2C12 cells, the expression of 
cyclin D3 is downregulated during myogenic differentiation. Therefore, it is 
possible that expression of Itm2a in C2C12 cells is involved in the upregulation 
of the expression of cyclin D3 during differentiation, and in this way indirectly 
related to establishment and maintenance of myogenic differentiation.  
Studies show that upon initiation of the differentiation process, the increase in 
cyclin D3 levels is accompanied by an increase in the  expression of the p21 in 
different myogenic cell lines, among them C2C12 (Franklin and Xiong, 1996; 
Duronio and Xiong, 2013). The increase in the levels of cyclin D3 during 
differentiation promotes the formation of the CDK4-cyclin D3 complex, which then 
interacts with p21. The induction of p21 inhibits the progression of the cells into 
the S phase where the DNA synthesis takes place (Cenciarelli et al., 1999; 
Williamson et al., 2009). However, the maintenance of the upregulation of p21 
during differentiation is not necessary for the maintenance of the cell cycle 
withdrawal. p21 is unstable with a half-life of 30 minutes, and acts quickly on the 
cell cycle, while the CDKIs that belong to the INK4 family have half-lives in the 
range of 4 to 6 hours and produce long-term cycle arrest (Franklin and Xiong, 
1996; Duronio and Xiong, 2013). Therefore, it would be necessary to study the 
expression of the different CDKIs during the differentiation of the C2C12 after 
ITM2A silencing to understand if ITM2A could be involved in their regulation. 






Intriguingly, CDKN2A (also known as p16INK4) was identified as an ITM2A-
interacting protein by mass spectrometry. Given the role of Itm2a in C2C12 
differentiation, it is possible that it can directly stimulate the function of this 
CDK4/6 inhibitor to accelerate cell cycle exit. Analysis of p16INK4 levels in 
scramble and shItm2a cells will be necessary to explore if they are 
mechanistically related.  
These results suggest that the expression of Itm2a in the C2C12 cell line plays 
an important role in the expression of cell cycle regulators. Particularly, the delay 
in differentiation of C2C12 cells with reduced Itm2a might be attributed to failure 
to upregulate cyclin D3 levels. However, this can only be suggested as this 
analysis has not been confirmed with biological replicas. Further studies should 
be carried out to understand if Itm2a is involved indirectly in the stabilization of 
the main complexes involved in the maintenance of the cell cycle withdrawal 
required for the differentiation of myoblasts into myotubes. The potential physical 
interaction with CDKN2 suggested by the proteomics analysis, is an attractive 
starting point to further investigate this process. More studies would allow the 
identification of the specific regulatory mechanisms involved in the changes of 
the cell cycle induced by ITM2A silencing.   
To have a better understanding on how the silencing of Itm2a is modifying the 
cell cycle progression, flow cytometry studies could be carried out in actively 
cycling myoblasts and during differentiation into myotubes to elucidate changes 






















Chapter 7                                                                              
Final conclusions 
Our published research shows that the CTD of PTCH1 mediates an autophagic 
flux blockade through interaction with ATG101 (Chen et al., 2018). The results 
that I generated, presented in Chapter 3, were used in the published paper to 
demonstrate that endogenous PTCH1 downregulates autophagic flux. This is 
relevant as it suggests that the mutations characterised in the next chapter could 
modify autophagy when expressed at endogenous levels.  
 
Continuing with this investigation, I generated constructs encoding three different 
somatic mutations in the CTD of PTCH1 that are overrepresented in colorectal, 
stomach and endometrial cancer and showed that the interaction between 
PTCH1 and ATG101 occurs in the region comprising amino acids 1308-1447. 
Nevertheless, the CTD construct that, although validated by Sanger sequencing, 
was not detected by western blot, needs to be generated for future analysis of 
different PTCH1-interactin proteins. A new cloning strategy could include the 
addition of an N-terminal tag instead of  the current C-terminal, or the use of a 
different tag unable to form polyproline helixes in the context of a proline-rich 
sequence.  
Of importance,  the results presented in Chapter 4 suggest that the cancer 
mutations in the CTD of PTCH1 that loss the ability to interact with ATG101, also 
lose their ability to inhibit the autophagic flux. Therefore, these mutations could 
be giving an advantage for cancer cells to survive without the restrictive role of 
PTCH1 on the regulation of autophagy. Further studies in more relevant cell lines 
and animal models are required to understand the pathological consequences of 






these somatic mutations. Nevertheless, the results presented in Chapter 4 
strongly suggest that the tumour suppressor role of PTCH1 is not limited to its 
inhibitory action on SMO and highlights the importance of the investigation of 
mutations in the CTD of PTCH1 that have not been previously appreciated, as 
they are not involved in the activation of the Hh canonical pathway. In the future, 
the identification of these mutations could be used as a biomarker for specific 
cancers (colorectal, stomach and endometrial). Also, as these mutations 
potentially enhance survival of cancer cells by stimulating autophagy, the use of 
autophagy inhibitors could be considered for treatment.  
 
I first started investigating the function of ITM2A with the hypothesis that it was a 
mediator of the autophagic flux regulated by PTCH1. Results in Chapter 5 show 
that even when PTCH1 and ITM2A interact with each other, they block 
autophagic flux independently of each other. Strikingly, expression of ITM2A 
caused a downregulation of PTCH1 expression, suggesting an unforeseen 
function of ITM2A in the regulation of PTCH1 stability and, importantly, in the 
regulation of the canonical Hh pathway. The effect of ITM2A on PTCH1 stability 
was observed in the different cell lines. Therefore, the first step toward elucidating 
the function of ITM2A in the Hh signalling pathway would be the generation of 
complete ITM2A knockouts in different cell lines, particularly in the ones with 
higher ITM2A endogenous levels. CRISPR/Cas 9 technology could be used for 
obtaining ITM2A knockout, now that the technology is widely used in the lab. It 
would also be relevant to generate an ITM2A knockout cell line in NIH3T3 cells 
to further study the effect of ITM2A in the Hh canonical pathway.  
 






The findings reported here (Chapter 5 and 6), as well as the studies published 
elsewhere, clearly show that the effects of the expression of ITM2A depend 
greatly on the cell type that is being investigated. Results obtained by a different 
group showed that the loss of ITM2A in samples from invasive serous ovarian 
cancer was highly common. Loss of ITM2A was a characteristic of around 45% 
of the analysed tissue samples. The expression of ITM2A in patient samples, as 
well as on ovarian cancer cell lines, revealed that expression of ITM2A was 
directly related to cell growth. While higher expression levels of ITM2A caused a 
reduction in cell growth and a reduction in cell colony formation. Importantly, the 
expression of ITM2A render the ovarian cancer cells more susceptible to the 
chemotherapy agents Paclitaxel and Carboplatin (Nguyen et al., 2016). This 
study is in line with the results presented in Chapter 5 corresponding to HeLa 
cells, in which the silencing of ITM2A caused a statistically significant decrease 
in the cells doubling time. This suggests that ITM2A could potentially be playing 
a positive role in the proliferation of HeLa cells or reducing their apoptotic index. 
However, further studies are necessary to understand the changes in the kinetics 
of cell proliferation and apoptosis in HeLa cells regulated by ITM2A.  
 
The results presented in Chapter 6, showing the changes in the expression of 
cyclin D3 during myogenic differentiation of C2C12 myoblasts after Itm2a 
silencing correspond to a single biological replica, and therefore, biological 
repeats are required to validate the reproducibility of results, to draw conclusions 
and to have a better understanding of how to move forward to further analyse the 
role of Itm2a and myogenic differentiation. The results from the proteomic 






analysis also provide a good starting point for future analysis of potential 
interacting partners and the processes affected. 
It would also be important to optimise the conditions for the mass spectrometry 
analysis of ITM2A. The PTM analysis showed in Chapter 6  was obtained using 
only trypsin to digest the ITM2A pulldowns. A future analysis using different 
proteases would provide a higher coverage percentage of the protein and 
therefore the identification of potential PTMs that can be modified to explore the 
function of ITM2A.  
 
Overall, this thesis shows a tumour suppressor role of PTCH1 that is independent 
of its role as SMO repressor, and also a new exciting role of ITM2A in the 
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